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MRC/DBT  Workshop UK-India Centre for Advanced Technologies-Minimising 
the indiscriminate use of Antibiotics (UKICAT–MA) 
 
 
14th/15th March 2016, Hyderabad, India 
  
Preface 
 
On 14/15th March 2016 we held a MRC/DBT funded workshop on the theme of  
Materials to Combat Antibiotic Resistance. The workshop was part of a continuing 
series of events that are part of the work of UK-India Centre for Advanced 
Technologies-Minimising the indiscriminate use of Antibiotics (UKICAT–MA).  The 
following is the collection of presentations and the results of discussions highlighting 
key themes for future work by this group. 
 
Combating antibiotic resistance is perhaps the biggest issue facing the global 
community in the 21st century and no other area, with the exception perhaps of 
nuclear conflict, has the capacity to significantly reduce living standards and mortality 
rates. Key objectives identified by WHO1 in this area among five key aspects, 
include: 
 
Objective 4-to optimize the use of antimicrobial agents 
Objective 5-new medicines, diagnostic tools, vaccines and other interventions 
  
Our aims in this series of workshops are to provide an Indo-UK forum for: 
discussions of our advances in providing technologies to address these objectives; 
facilitate the interface between UK and Indian clinicians, materials and biological 
scientists and to identify key areas for new projects. An important aspect of the work 
in a global context is that by combining the UK and Indian community and clinical 
experiences we cover most of the scenarios that the global population might expect to 
encounter.  
 
Our first workshop focused on bringing together materials experts, microbiologists 
and clinical practitioners and scientists. On clinical aspects Prashant Garg and Ian 
Douglas both provided presentations that set the scene and discussed the environment 
for antibiotic resistance that is causing such great concern. Savitri Sharma, 
emphasized the role that fungal infections play in tropical climates.  
 
Subhadeep Chatterjee provided key insights into the role of quorum sensing and 
pointed out some of the key molecules that might provide useful technological targets. 
 
A wide range of useful technologies were presented at the workshop. In terms of 
emerging technology we heard about a number of novel delivery systems from Vamsi 
Krishna Vanugentu, Pradip Paik and Saptarshi Majumdar. Vamsi Krishna Vanugentu 
described the use of electrical charge to promote diffusion of nanoparticles towards 
the infective tissues. Pradip Paik discussed a several nanoparticle delivery systems 
and showed how molecular imprinting might be used to selectively bind important 
biomolecules and pointed out the importance of chirality. Saptarshil Majumber 
discussed their work on delivery from hydrogels, fibres as well as coarse grain 
modeling of polymer behaviour in aqueous media. Joey Shepherd showed us how 
ultra-sound could be used to break up biofilms. This MRC/DBT project is mainly 
funded to further our work on branched polymers that are responsive to bacteria and 
Stephen Rimmer provided an update of our progress in this area and showed how 
responsive polymers can be used to target different organisms.  
 
1 WHO. Global Action Plan on Anti-microbial Resistance.  (2015). 
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Bacterial Resistance: 
A Growing Concern 
Prashant Garg; MD 
L V Prasad Eye Institute, 
Hyderabad 
•  Phenomenon of drug resistance 
•  State of affairs for systemic infections 
•  State of affairs for ocular infections 
•  Global initiative 
•  Lessons we can learn 
Antibiotic Resistance 
Objective 
Pathogens continue to evolve 
Antibiotics are expected  
to become  
less effective over time 
Antibiotic Resistance 
Antibiotic 
Antibiotic 
Antibiotic 
Antibiotic 
Antibiotic Resistance 
Challenges 
•  Serious public health concern for diseases 
such as Malaria & Tuberculosis 
•  Increasingly being reported for common 
bacterial diseases 
•  Multi-drug resistance 
•  No more a “Hospital acquired 
phenomenon” 
Antibiotic Resistance 
Challenges 
•  Difficult to manage 
•  Associated with increased morbidity & 
mortality 
•  Increased duration of hospital stay 
•  Increased health care cost 
Antibiotic Resistance 
Challenge 
Infections 
•  1998 adopted a resolution urging member 
states to take necessary actions 
•  2001 published “WHO global strategy on 
containment of antimicrobial resistance” 
•  Surveillance of AMR as an essential part of 
the action plan 
Antibiotic Resistance 
WHO Initiative 
•  Trends of pathogens and AMR & regional 
variations 
•  Relationship between antibiotic use & 
resistance 
•  Assessment of outcomes interventions 
Antibiotic Resistance 
Surveillance 
Important objectives 
•  IDSR in Africa 
•  ReLAVRA in Canada 
•  ARMed in Mediterranean 
•  EARS-net for European union 
•  WHONET 
Antibiotic Resistance 
WHO Initiative 
AMR surveillance 
•  NHSN 
•  PROTEKT 
•  SENTRY 
•  EARSS 
•  SMART, TSN, TRUST 
Antibiotic Resistance 
Regional Initiatives 
AMR surveillance 
What are the important observations of 
these surveillance systems? 
Antibiotic Resistance 
WHO Initiative 
•  There is a clear association between use of 
antibiotics & AMR. 
•  Time required for the development of 
resistance is much shorter as compared to 
decay after cessation. 
Antibiotic Resistance 
Surveillance 
Important Observations 
Antibiotic Resistance 
Oxacillin resistance for S.aureus increased but is stabilizing. 
•  Oxacillin resistance for S.aureus increased 
but is stabilizing.  
•  There is general increase in resistance 
among gram negative pathogens. 
Antibiotic Resistance 
Surveillance 
Important Observations 
Antibiotic Resistance 
Surveillance 
•  Oxacillin resistance for S.aureus increased 
but is stabilizing.  
•  There is general increase in resistance 
among gram negative pathogens. 
•  There is increasing trends toward 
combined resistance 
Antibiotic Resistance 
Surveillance 
Important Observations 
Antibiotic Resistance 
Surveillance 
•  Resistance among E. coli for ciprofloxacin 
increased from 3% in 2000 to 17.1% in 2010 
•  Resistance among Acinetobacter to 
imipenem  increased from 23.9% to 34.3%.  
•  Resistance to piperacillin-tazobactam 
increased from 37% to 49.7%. 
Antibiotic Resistance 
Surveillance 
Important Observations 
What is the status of resistance among 
ocular isolates? 
Antibiotic Resistance 
Antibiotic Resistance 
Ophthalmology 


Initial Euphoria 
•  Wide spread use in treatment of 
conjunctivitis, keratitis 
•  Systemic therapy  
•  Prophylaxis against postoperative 
infection 
Antibiotic Resistance 
Fluoroquinolones 
Antibiotic Resistance 
Fluoroquinolones 
1. Mah F. Ophthalmol Clin North Am. 2003;16:11-27; 2. Marangon FB, et al. Annual Meeting of the Association for Research in Vision and 
Ophthalmology; May 5, 2002; Ft. Lauderdale, Fla. Abstract. 3. Ritterband DC, et al. Annual Meeting of the Association for Research in Vision 
and Ophthalmology; May 6, 2002; Ft. Lauderdale, Fla. Abstract. 
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Antibiotic Resistance 
Fluoroquinolones 
Advantages 
•  Broad spectrum activity 
•  Superior activity against quinolone resistant 
isolates 
•  Superior kill kinetics 
•  Improved eradication of bacteria 
8-methoxy fluoroquinolones 
Antibiotic Resistance 
Ciprofloxacin Gatifloxacin Moxifloxacin 
Cipro sensitive Gram 
+ ive 
0.3 (0.08-1) 0.09 (0.03-0.5) 0.09 (0.03-0.5) 
Cipro resistant Gram 
+ ive 
32 (4-32) 1.5 (0-32) 1.75 (0.2-32) 
Cipro sensitive Gram 
- ive 
0.19 (0.13-0.75) 0.5 (0.05-3) 2 (0.13-8) 
Cipro resistant Gram 
- ive 
32 (32-32) 32 (32-32) 32 (32-32) 
MIC in 2002 
Antibiotic Resistance 
Fluoroquinolones 
Ciprofloxacin Gatifloxacin Moxifloxacin 
Cipro sensitive Gram 
+ive 
0.3 (0.08-1) 0.09 (0.03-0.5) 0.09 (0.03-0.5) 
Cipro resistant Gram 
+ive 
32 (4-32) 1.5 (0-32) 1.75 (0.2-32) 
Cipro sensitive Gram 
-ive 
0.19 (0.13-0.75) 0.5 (0.05-3) 2 (0.13-8) 
Cipro resistant Gram 
-ive 
32 (32-32) 32 (32-32) 32 (32-32) 
MIC in 2002 
Antibiotic Resistance 
Fluoroquinolones 
Antibiotic Resistance 
Fluoroquinolones 
Organism 
Susceptibility 
N Gatifloxacin sensitivity (%) 
Moxifloxacin 
sensitivity (%) 
Cipro sensitive S.aureus 39 39 (100) 37 (94.9) 
Cipro resistant S.aureus 97 40(41.2) 7 (7.2) 
Cipro sensitive CONS 120 120 (100) 103 (85.3) 
Cipro resistant CONS 111 84 (75.7) 28 (25.2) 
Cipro sensitive S.pneumoniae 301 294 (97.7) 251 (83.5) 
Cipro resistant S.pneumoniae 5 2 (40) 1 (20) 
Antibiotic Resistance 
Fluoroquinolones 
Pseudomonas 
Susceptibility % 
Antibiotic  2009 2010 2011 2012 
Amikacin 71.64 50.44 40.13 35.96 
Gentamicin 64.18 47.79 40.13 32.46 
Ceftazidime 38.81 37.17 37.66 33.33 
Ciprofloxacin 50.71 48.67 37.66 32.46 
Gatifloxacin 62.69 48.67 37.66 35.09 
Moxifloxacin 50.75 42.48 35.81 29.82 
Antibiotic Resistance 
Pseudomonas 
Susceptibility % 
Antibiotic  2009 2010 2011 2012 
Amikacin 71.64 50.44 40.13 35.96 
Gentamicin 64.18 47.79 40.13 32.46 
Ceftazidime 38.81 37.17 37.66 33.33 
Ciprofloxacin 50.71 48.67 37.66 32.46 
Gatifloxacin 62.69 48.67 37.66 35.09 
Moxifloxacin 50.75 42.48 35.81 29.82 
Antibiotic Resistance 
•  Very well known in Ophthalmology & to 
Ophthalmologists. 
•  Most literature on resistance came from 
individual laboratories.  
•  Until last decade we did not have national 
or regional surveillance 
Antibiotic Resistance 
Ophthalmology 
•  TSN: 2000 – 2005 S aureus 
•  Ocular TRUST study: S aureus, S pneumoniae, 
& H influenzae  
•  ARMOR 2009: S aureus, coagulase-negative 
Staphylococci, S pneumoniae, H influenzae & 
P. aeruginosa  
Antibiotic Resistance 
Ophthalmology 
AMR surveillance 
•  Asia Cornea Society Infectious 
Keratitis Study 
Antibiotic Resistance 
Ophthalmology 
AMR surveillance 
ACSIKS	Study	
India	
Japan	
Korea	
Philippines	
Singapore	
Taiwan	
Thailand	
Shandong	Eye	Ins;tute	
Xiamen	Eye	Centre	
Aravind	Eye	Hospitals	
LV	Prasad	Eye	Ins;tute	
ToBori	University	Faulty	of	Medicine	
Osaka	University	Graduate	School		
of	Medicine	Hospital	
China	
Seoul	St	Mary	Hospital	
Philippine	General	Hospital	
Singapore	Na;onal	Eye	Centre	
Na;onal	Taiwan	University	Hospital	
Siriraj	Hospital	Mahidol	University	
8	Countries	 12	Study	Centres	 27	Par;cipa;ng	Ins;tu;ons	
•  Qingdao	Eye	Hospital	
•  Shandong	Eye	Hospitals	
•  Eguchi	Eye	Hospital,	Hokkaido	
•  Miyata	Eye	Hospital,	Kyusu	
•  Kansei	Rousai	Hospital	
•  Otemae	Hospital	
•  Ideta	Eye	Hospital	
•  Okamoto	Eye	Clinic	
•  Kim’s	Eye	Hospital	
•  Bundang	Seoul	Na;onal	University	Hospital	
•  East	Avenue	Medical	Center	
•  KK	Women’s	and	Children’s	Hospital	
•  Changi	General	Hospital	
•  Na;onal	University	Hospital	
•  Tan	Tock	Seng	Hospital	
•  Khoo	Teck	Puat	Hospital	
Kyoto	Prefectural	University	
ACSIKS 
Ophthalmology 
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ACSIKS  Actual Recruitment ACSIKS  Projection 
SITE NO. SITE Actual Recruitment 
111 Qingdao Eye Hospital (QEH) 178 
112 Shandong Eye Hospital (SHA) 250 
120 Xiamen Eye Centre (XEC) 512 
China Total 940 
210 Aravind Eye Hospital (AEH) 2323 
220 LV Prasad Eye Institute (LVPEI) 1358 
India Total 3681 
310 Tottori University Hospital (TUH) 58 
311 Eguichi Eye Hospital (EEH) 6 
312 Miyata Eye Hospital (MEH) 91 
320 Osaka University Grad School of Med Hospital (OUH) 54 
321 Kansei Rousai Hospital (KRH) 8 
322 Otemae Hospital (OH) 15 
323 Ideta Eye Hospital (IEH) 20 
324 Okamoto Eye Clinic (OEC) 21 
910 Kyoto Prefectural University of Medicine (KPUM) 28 
Japan Total 301 
Enrollment Status by Country 
SITE NO. SITE Actual Recruitment 
410 Seoul St Mary Hospital (SSMH)  130 
411 Kim's Eye Hospital (KEH) 98 
412 Bundang Seoul National University Hospital (BSNUH) 22 
Korea Total 250  
510 Philippine General Hospital (PGH)  190 
511 East Ave Medical Center (EAMC)  161 
Philippines Total 351 
610 National Taiwan University Hospital (NTUH)  223 
611 Mackay Memorial Hospital (MMH)  7 
612 Taipei Tzu Chi General Hospital (TCGH)   3 
Taiwan Total 233  
710 Siriraj Hospital Mahidol University (SRH)  225 
711 King Chulalongkorn Memorial Hospital (KCMH) 55 
Thailand Total 280 
810 Singapore National Eye Centre (SNEC) 235 
812 KK Women's & Children's Hospital (KKH) 2 
813 Changi General Hospital (CGH) 174 
814 National University Hospital (NUH) 33 
815 Tan Tock Seng Hospital (TTSH) 55 
816 Khoo Teck Puat Hospital (KTPH) 34 
Singapore Total 533 
Enrollment Status by Country 
*Includes all 
cultures 
performed; 5000 
positive cultures 
Culture Positive Rate by Country 
Overall Micro-organism Distribution (N=2,886) 
*Includes only unique 
microorganisms per subject 
*Includes only unique 
microorganisms per subject 
Micro-Organism Distribution by Country 
15 
274 
124 
56 
16 
25 
35 
89 
Overall Top 5 
Strep. pneumoniae   27.9% (177) 
coagulase neg Staph    17.2% (109) 
P. acnes    13.9% (88) 
Staph. aureus   13.5% (84) 
Corynebacterium spp    7.9% (50) 
Gram-Positive Bacteria 
15 
274 
124 
56 
16 
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26 
33 
28 
64 
120 
Gram-Negative Bacteria 
Overall Top 5 
Ps aeruginosa  68.9% (312) 
Moraxella spp  3.5% (16) 
Serratia marcescens    3.1% (14) 
Klebsiella pneumoniae 3.1% (14) 
Enterobacter spp  2.6% (12) 
Overall Top 5 
Fusarium spp  518 (40.5%) 
Aspergillus flavus  238 (18.6%) 
Moulds  
   (non-sporulating)  190 (14.9%) 
Curvularia spp  61 (4.8%) 
Aspergillus  
   fumigatus  59 (46%) 
 125 
998 
14 
12 
90 
10 
23 
7 
Fungus 
What is the important observation of 
the surveillance studies? 
Antibiotic Resistance 
Ophthalmology 
•  The proportion of infections caused by 
MRSA increased from 29.5% in 2000 to 
41.6% in 2005 
•  MRSA were resistant to 3 or more class of 
antibiotics including fluoroquinolones 
Antibiotic Resistance 
Ophthalmology 
TSN-Ocular isolates 
Antibiotic Resistance 
Ophthalmology 
Ocular TRUST 
•  No increase or a marginal reduction of 
MRSA compared to 2005 (39% v/s 41.6%) 
•  Fluoroquinolones showed significant 
increase in inactivity against all Staph 
Antibiotic Resistance 
Ophthalmology 
ARMOR study 
•  Resistance among P. aeruginosa isolates to 
cephalosporins, fluoroquinolones & 
carbepenams is increasing 
•  This is a grave concern specially when 
only 36.0% of S. aureus & 21.5% of CNS 
being susceptible to entire drug classes 
Antibiotic Resistance 
Ophthalmology 
ARMOR study 
Antibiotic Resistance 
Ophthalmology 
•  AMR is a serious problem both for systemic & 
Ophthalmic infections.  
•  Resistance among Gram negative organisms 
and multi-drug resistance are serious threats. 
•  We need strong antibiotic policies for 
containing this challenge 
Conclusions 
Thank you! 
L V Prasad Eye Institute 
www.lvpei.org 
Excellence  •   Equity   •  Efficiency 
Drugs and Resistance 
Resistant Strains 
Rare 
Resistant Strains  
Dominant 
Antimicrobial  
Exposure   x x 
x x 
Drug Resistance 
Evolution 
New Resistant Bacteria 
Mutations 
XX 
Susceptible Bacteria 
Resistant Bacteria 
Resistance Gene Transfer 
Drug Resistance 
Evolution 
Year 
Methicillin 
Sensitive 
(%) 
Methicillin 
Resistant 
(%) 
CI (95%) P 
2006 33 (73.3) 12 (26.7) 13.3-38.7 
0.075 
 
 
2007 59 (64.9) 32 (35.1) 25.2-45.2 
2008 39 (61.9) 24 (38.1) 26.1-50.1 
2009 37 (64.9) 20 (35.0) 25.1–45.2 
Antibiotic Resistance 
Ophthalmology 
Antibiotic Resistance 
Antibiotic Resistance 
Ophthalmology 
Ocular TRUST 
Antibiotic Resistance 
Ophthalmology 
Ocular TRUST 
Antibiotic resistance –  
Its true biology and global spread 
Ian Douglas,  
University of Sheffield 
Sheffield and district 
Antibiotic era 
• Survival time of penumonia septicaemia 
– Average no antibiotic – 75% death in 14 
days  
– Average with penicillin – 15% death in 14 
days 
“The time may come when penicillin can be 
bought by anyone in the shops. Then there is 
the danger that the ignorant man may easily 
underdose himself and by exposing his  
microbes to nonlethal quantities of the drug 
make them resistant.” 
Alexander Fleming's Nobel Lecture, 1945 
 
Major classes of antimicrobials and 
the year of their discovery 
J. Davies 2009 
Inappropriate use 
Tanzania – neonatal Gram–ve sepsis 
Survival with inappropriate antibiotic treatment 20% in 14 
days 
Survival with appropriate antibiotic treatment 70% in 14 days 
 
Resolution of 
cough 
Post-antibiotic era 
• Inappropriate use selects resistance 
– Exposes resident organisms unnecessarily 
• Development of new antimicrobials has 
been behind the rapid evolution of 
resistance genes 
• In EU 25,000 die from multidrug resistant 
bacteria per year 
Evolution of antimicrobial resistance 
S.aureus 
(90% sens) 
penicillin 
(1947) 
1950’s 
Penicillin-resistant 
S.aureus 
(75% sens) 
Methicillin-resistant 
S.aureus (MRSA) 
(mecA gene) 
methicillin 
1980’s 
vancomycin 
Vancomycin resistant 
Enterococcus (vanA gene 
cluster) 
Vancomycin 
Intermediate 
resistant 
MRSA 
(not vanA-
dependent) 
Vancomycin 
resistant 
VRSA 
(vanA-
dependent) 
2002 
1990’s 
(5% 
resist) 
1997 
 We will not stop evolution! 
Resistance not entirely Darwinian 
• Most antibiotics come from soil organisms 
(where most pathogens don’t live) 
– They have both productive and self-protecting mechanisms 
• Assumed to be a weapon & shield 
• But is their aim to inhibit growth of competitors? 
– Antibiotic concentration in natural environments very low 
• Hormetic effect? 
• Antibiotics may serve as signalling molecules 
• Mutation rates can be higher when under stress 
– Can be triggered by environmental or metabolic signals 
– Subpopulations 
• ‘Bet hedging’ 
Antibiotic concentration 
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Antibiotic non-responsiveness 
• Antibiotic resistance – not killed and continue to 
grow 
– Develops over time e.g. mutations 
– Clinical problem is due to selective pressure -
Darwinian evolution  
• Antibiotic tolerance – not killed and not growing 
– There is a spectrum of sensitivities in a population 
• Persisters/dormant cells 
– Re-grow after antibiotics   
• Relevant to biofilms - 3D layered architecture, matrix can bind 
drug 
Biofilms pose particular difficulties 
• Green areas - 
respiratory activity 
• Red-orange areas – no 
respiratory activity 
•  Red cells are not dead 
– they are dormant 
• Yellow areas - mixture of 
activities 
• Mixed species biofilms 
offer opportunity for gene 
transfer 
Transfer of resistance 
•  DNA transfer 
– Plasmid 
– Chromosomal  
• Pathogens have acquired 
resistance genes from antibiotic-
producing organisms 
• Groups of resistance genes 
assembled into integrons  
Antimicrobial resistance 
• The target is structurally altered 
– Pencillin-binding proteins 
• The target is overproduced 
– Dihydropteroate synthetase and 
sulphonamide 
• The drug is removed 
– Enzymic destruction 
• b-lactamase 
• 3 enzymes modify aminoglycosides 
– Efflux pumps 
• Tetracyclines, quinolones 
• The drug cannot penetrate cell 
Unexpected mechanisms 
• Fluoroquinalone resistance 
– Aminoglycoside-modifying enzyme also acts on a 
fluoroquinolone  - chemically different molecule 
– An N-acetyltransferase that  modifies  bacterial  
peptidoglycan can inactivate gentamicin - structural 
mimicry 
• SOS response 
– Defective cell wall synthesis can initiate SOS response,  
• β-lactam antibiotics are extracellular stimuli of the SOS 
response 
– Transiently halts bacterial cell division,  
• survival of lethal antibiotic exposure.  
• Antibiotics can induce competence 
– Chance of acquiring  DNA higher when cell death 
occurring 
Broad spectrum antibiotics 
• Advantage for clinician 
– Need not worry about aetiological agent 
• Longer term disadvantage 
– Selective pressure, not only on aetiological agent 
but also upon a large fraction of commensals 
• Transfer of resistance from commensals to 
pathogens in man 
• Use of antibiotics in farming 
– Transfer from animal commensals to human 
pathogens 
So what are the big issues? 
 
• Lack of regulation and surveillance 
– Athens, 2008  
• 100% of pharmacies sold co-amoxiclav over the counter 
• 53% sold ciprofloxacin despite restrictions 
– Mexico City 
• 30% of antibiotics sold without medical prescription 
– Simple ban? 
• Developing countries - self-prescription often only means of 
medical treatment 
• Lack of or slow development of new agents 
– No financial incentives for pharma 
• Lack of sophisticated ways to control infection 
– Knowing the target pathogens quickly 
– Knowing how to control ‘persisters’ 
So what are the solutions? 
• Modification to clinical practices 
– Reduce the driver for Darwinian evolution 
• Prescribe as infrequently as possible 
• Prescribe the correct dose for the shortest duration to achieve clinical 
cure 
• Aim the antibiotics at the organisms present  
– Requires knowledge of local sensitivity patterns 
• New classes of agents 
– Improve financial incentives for pharma 
• Resurrect abandoned agents 
– Government-sponsored research 
• Rapid detection of infection and identification of culprit 
organisms 
• Delivery of high concentrations of targeted agents 
– Systems to get agents at high concentration into biofilms 
• Systems to trick bacteria out of dormancy 
Conclusion 
• Antibiotic Resistance- a collective failure of 
– public policy & global governance 
– research prioritisation 
– the current market system 
Thank you 
Reasons why antibiotics fail 
• Poor patient compliance 
– Can we change human nature? 
• Agent does not reach the site 
– Inadequate drainage of abscesses 
– Poor blood supply (inc. foreign body)  
– Inadequate duration 
• Impaired defences 
– Immunocompromised (& bacteriostatic) 
• Inappropriate agent - resistance 
– Inherent; acquired (mutation, plasmids)  
BITS Pilani
Hyderabad Campus
Layer-by-layer self-assembled 
nanoparticles and thin films for 
topical drug delivery applications
V. Vamsi Krishna Venuganti, PhD
Assistant Professor
Department of Pharmacy
BITS Pilani, Hyderabad Campus
15th March, 2016
BITS Pilani, Hyderabad Campus
Drug Delivery Platforms
Nanoparticle-based 
system
• LbL 
Nanoparticles
• Liposomes
Polymeric thin 
films
Microneedle 
array
BITS Pilani, Hyderabad Campus
Layer-by-layer assembly 
J. J. Richardson et al., Science 348, aaa2491 (2015)
BITS Pilani, Hyderabad Campus
Layer-by-layer 
assembly technologies
J. J. Richardson et al., Science 348, aaa2491 (2015)
BITS Pilani, Hyderabad Campus
Scheme for LbL Nanoparticle 
skin application
BITS Pilani, Hyderabad Campus
Characterization of LbL-AuNP
Labala et al. Molecular Pharmaceutics 2015, 2: 878-888
BITS Pilani, Hyderabad Campus
Stability of LbL-AuNP
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a. Effect of NaCl concentration on localized
surface plasmon resonance (SPR) wavelength
of AuNP. b. Photograph of effect of NaCl
concentration on stability of AuNP.
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Imatinib loaded LbL-AuNP
Labala et al. Molecular Pharmaceutics 2015, 2: 878-888
BITS Pilani, Hyderabad Campus
Labala et al. Molecular Pharmaceutics 2015, 2: 878-888
BITS Pilani, Hyderabad Campus
Skin permeation of IM loaded 
LbL-AuNP
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Skin permeation of IM loaded 
LbL-AuNP
Labala et al. Molecular Pharmaceutics 2015, 2: 878-888
BITS Pilani, Hyderabad Campus
Cell uptake and cell viability 
studies
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siRNA loaded LbL-AuNP
BITS Pilani, Hyderabad Campus
Cell viability study in B16F10
BITS Pilani, Hyderabad Campus
Cell uptake of LbL-AuNP
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Mechanism of cell uptake
BITS Pilani, Hyderabad Campus
STAT3 expression and apoptosis 
events in B16F10 cells
a, untreated cells; b, free STAT3
siRNA; c & d, AuNP-CS/SA/CS
containing 338 µM and 675 µM
of AuNP; e & f, AuNP-
CS/Scrambled-siRNA/CS at 0.25
nM and 0.5 nM; g & h, AuNP-
CS/STAT3-siRNA/CS at 0.25 nM
and 0.5 nM, respectively
BITS Pilani, Hyderabad Campus
Skin penetration of siRNA 
loaded LbL-AuNP
BITS Pilani, Hyderabad Campus
In-vivo application of 
iontophoresis
Venuganti et al. Nanoscale. 2015, 7(9):3903-14
BITS Pilani, Hyderabad Campus
2. Layer-by-layer thin films for topical 
applications
BITS Pilani, Hyderabad Campus
Characterization of LbL films
Mandapalli et al. Eur J Pharm Sci 83 (2016) 166–174
BITS Pilani, Hyderabad Campus
Physical characteristics of LbL 
blank films
BITS Pilani, Hyderabad Campus
Parameter Value
Thickness (μm) 15 ± 1.0
Porosity (%) 27 ± 5.2
Swelling index (%) 32 ± 3.2
Burst strength (N/cm2) 1.1 ± 0.09
Tensile strength (MPa) 0.013 ± 0.001
Elastic modulus (N/cm2) 39.6 ± 3.2
Elongation (%) 3.56 ± 0.2
Adhesion strength (N/cm2) 2.22 ± 0.08
Work of adhesion (N/cm2) 0.37 ± 0.04
Physical characteristics of LbL 
blank films
Data are presented as mean (n = 3) ± SD.
BITS Pilani, Hyderabad Campus
BITS Pilani, Hyderabad Campus
Characterization of siRNA 
loaded LbL films
BITS Pilani, Hyderabad Campus
Excisional wound healing 
studies
BITS Pilani, Hyderabad Campus
Excisional wound healing 
studies
BITS Pilani, Hyderabad Campus
Histological examination of 
wounded skin
BITS Pilani, Hyderabad Campus
• Layer-by-layer polyelectrolyte coating on AuNP would
improve their stability in bio-relevant medium.
• High charge density on the LbL-AuNP would allow rapid
cell uptake and allow iontophoresis application for skin
transport.
• LbL thin films can be developed to loaded small and
macromolecule drugs for topical applications on
compromised skin.
Conclusions
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Smart Self-healable Hydrogel based on Polymer 
Nanocomposite for Bio-medical Application 
 
DBT-MRC Workshop March 14-15, 2016 
•  Design of polymeric/rubber products 
•  Polymer blends  
•  Controlled/Living Radical Polymerization (CRP)  
•  Synthesis of Functional Polymers, Block and graft copolymers 
•  Preparation of smart materials by CRP & “Click Chemistry” 
•  Polymers in Bio-medical Applications  
•  Adhesives, Paints & Coatings (UV Curable, Reversible) 
•  Polymer Nanocomposites  via in situ CRP 
•  Ionic liquids in polymers 
•  Polymer Nanocomposites  
•  Thermoplastic elastomers  
•  Polyurethane (incl. fire retardant) Synthesis 
•  EMI Shielding materials 
 Research Program in My Centre/ Research Group 
3 
What is hydrogel ? 
A hydrogel is a macromolecular polymer gel constructed of a network of crosslinked 
polymer chains. Hydrogels are synthesized from hydrophilic monomers by either chain 
or step growth, along with a functional crosslinker to promote network formation. A 
net-like structure along with void imperfections enhance the hydrogel's ability to absorb 
large amount of water via hydrogen bonding. 
4 
What is self healing hydrogel? 
Self-healing refers to the spontaneous formation of new bonds when old bonds are broken 
within a material. The structure of the hydrogel along with electrostatic attraction forces 
drive new bond formation through reconstructive covalent dangling side chain or non-
covalent hydrogen bonding. These flesh-like properties have motivated the research and 
development of self-healing hydrogels in fields such as reconstructive 
tissue engineering as scaffolding, as well as use in passive and preventive applications. 
Viswanathan et.al. Nature,  (2001), 409(6822), 794. 
5 
Chemically 
croslinked 
Physically 
crosslinked 
Radical polymerization 
Addition and 
Condensation 
Polymerization 
Gamma and Electron 
Beam Polymerization 
Ionic interactions 
Crystallization 
Hydrogen bonds 
Protein interaction 
Synthesis methods of hydrogel 
Different 
methods of 
preparation of 
hydrogel 
Stimuli responsive hydrogel 
pH responsive 
Thermo 
responsive 
Light responsive 
 
7 
Different mechanisms of self healing in polymer gel 
Diels Alder (DA) & rDA Reaction in Polyfurfuryl 
Methacrylate (PFMA) 
Reaction Scheme: 
Click Reaction 
Gandini et al, Macromolecules 2002 
Wudle et al Science 2002  
Kavitha & Singha  J. Polym. Sci. Polym. Chem. 2007 
Kavitha & Singha Macromolecules 2010 
Thermo-reversible Self-healing DA Polymer 
(b) 
notch 
(a) 
very smooth  
(c) 
Heated at 120 °C (1 h) 
(d) 
2 h 
(e) 
3 h 
(f) 
4 h 
Kavitha & Singha ACS Applied Materials & Interfaces, 1, 1427 (2009), Macromolecules 2010. 
Self-repairing  Properties of  Polyfurfuryl methacrylate via FE-SEM analysis  
a) Cross-linked DA polymer (PFMA-
co PBMA/BM) insoluble in toluene at 
30 °C, b) soluble after heated at 120 
°C, c) Reformed polymer was gelled 
when this soluble polymer was cooled, 
d) Insoluble polymer at 30 °C.	
Healing & Thermoreversibility of Copolymer/BM adduct 
Polymer 2015 
SEM images of  healing of a notch on 
copolymer/BM DA  adduct healed with time  
on heating  & cooling followed by cooling at 
50 °C for 24 hr.  a) notch surface,  b) 1 h, c) 
2 h, d) 4 h.  
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AIBN or KPS 
Water/TritonX405 
75°C 
NC
H3C
H3C
CH2 CH
O
S
C
S
S C12H25n
CH2
O
CF2
CF2
CF3
PHFBA 
Butyl Acrylate 
AIBN or KPS 
Water/TritonX405 
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CH2 CH
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O
CH2
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S
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PHFBA-b-PBA 
2,2,3,3,4,4,4-
Heptafluorobut
yl acrylate 
(HFBA) 
2-cyano propyl 
dodecyl 
trithiocarbonat
e (CPDTC)    
PHFBA 
PHFBA-b-BA 
Chain Extension 
BA 
Aggregation of PHFBA 
RAFT end 
group 
Element  Wt %  At % 
 C K 78.38 84.37 
 O K 10.89 08.80 
EDX	of	core	
Element  Wt %  At % 
C K 87.03 90.17 
 O K 10.88 08.46 
 F K 02.09 01.37 
EDX	of	shell	
Core-shell fluorinated block copolymer  With improved hydrophobicity  
Chakrabarty & Singha;  
J. Colloid. Interface Science 2013, 
 408, 66-74  
Materials used for hydrogel preparation 
OH
OH
HO
O O
HO
OH
OH
O
COOH
O
O
N
Cl
Starch (Str)  Acrylic acid 
(AA) 
2-acryloyloxy)ethyl trimethyl 
ammonium chloride (AETAC) 
H
N
H
N
O O
M
B
AOrganically 
modified clay 
(OMMT) 
Prepared 
hydrogel 
Yield% = ​​W↓c /​W↓i   X100 
Gel% = ​​W↓d /​W↓c   X100 
Sol% = (100 – Gel%) 
Yield % = 90 
Gel % = 85 
 
Wc = Constant weight of 
the hydrogel after drying; 
Wi = the weight of total 
monomer taken; 
Wd = Constant weight of 
the hydrogel after 
equilibrium swelling and 
subsequent drying 
Starch 
Scheme of hydrogel preparation 
Composition of different hydrogel 
Sample code Starch 
 (wt%) AA : AETAC 
MBA  
(wt% w.r.t total 
monomer ) 
OMMT 
 (wt% w.r.t 
monomer) 
SBase 2.0 70:30 1.0 0.0 
S0 2.0 70:30 1.0 2.5 
S1 2.0 70:30 1.0 5.0 
S2 2.0 70:30 1.0 7.5 
S3 2.0 70:30 1.5 5.0 
S4 2.0 70:30 2.0 5.0 
S5 0.0 70:30 1.0 5.0 
S6 3.0 70:30 1.0 5.0 
S7 2.0 50:50 1.0 5.0 
S8 2.0 90:10 1.0 5.0 
Total batch volume = 20 ml; APS =  1 wt% w.r.t monomer amount 
Characterization of prepared OMMT (FTIR and 
XRD analysis) 
(d-spacing = 1.46 nm) 
(d-spacing = 1.65 nm) 
Characterization of prepared hydrogel (FTIR) 
Characterization of prepared hydrogel (FESEM Analysis) 
SEM analysis of  
(a) Hydrogel without 
containing filler,  
(b) & (c) Composite 
hydrogel with different 
content of OMMT,  
(d) Bulk phase elemental 
mapping of the filler 
loaded hydrogel.  
(e) EDAX analysis of 
filler loaded hydrogel. 
 
Characterization of prepared hydrogel  (TEM Analysis) 
Polymer 
hydrogel 
External viscous 
force Internal elastic 
force 
Polymer 
hydrogel 
External 
viscous  
force 
Swelling and deswelling study 
Swelling study of the 
prepared hydrogel with 
variation in  
a)  Different amount of 
crosslinker,  
b)   in different amount 
of OMMT.  
c)  Swelling study of 
hydrogel in different 
salt solution.  
d)   Swelling study of the 
hydrogel containing 
5 wt% OMMT at 
pH=1.2 and pH=7.4 
solution.  
e)  Deswelling behavior 
of the hydrogel at 
varying content of 
starch. 
 
Study of pH responsiveness 
AA	:	AETAC	(90	:	10)	
AA	:	AETAC	(70	:	30)	
AA	:	AETAC	(50	:	50)	
Compression set and bending study of the hydrogel 
(i) Image of compression set study of the composite hydrogel a. before 
compression, b. during compression and c. after compression. (ii) Bending test 
of the composite hydrogel. 
Self healing study of the hydrogel 
Self-healed hydrogel in different pH Elongation study of self- 
healed hydrogel 
1 M NaCl 
0.154 M 
NaCl 
pH = 7.4 
pH = 1.2 
i) Self healing study of the hydrogel at different 
conditions a) pH 1.2 b) pH 7.4  c) 0.154 (M) NaCl soln.  
d) 1 (M) NaCl soln. e) Only Acrylic acid based gel f) 
Only AETAC based gel 
Rheological study of the hydrogel 
(a) Storage modulus (G') change vs Strain in uncut hydrogel and 
self-healed hydrogel, (b) Loss modulus (G'') change vs Strain in 
uncut hydrogel and self-healed hydrogel and (c) Plot of G' & G'' 
vs Strain for pure hydrogel and composite hydrogel containing 
5.0 wt% filler. 
Non-leaching Antimicrobial study 
Mechanism of 
non-leaching 
antimicrobial 
activity 
a) Ciprofloxacin loaded 
hydrogel 
b) pure hydrogel 
c) OMMT incorporated 
hydrogel 
Haemocompatibility study 
Hemolysis ratio (%) = ​​𝑺𝒖𝒔𝒑𝒆𝒏𝒔𝒊𝒐𝒏𝒔↓𝑨𝒃𝒔 − ​𝐍𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝒄𝒐𝒏𝒕𝒓𝒐𝒍↓𝑨𝒃𝒔 /​𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝒄𝒐𝒏𝒕𝒓𝒐𝒍↓𝑨𝒃𝒔 − ​𝐍𝐞𝐠𝐚𝐭𝐢𝐯𝐞 𝒄𝒐𝒏𝒕𝒓𝒐𝒍↓𝑨𝒃𝒔   X 100 
•  For the composite hydrogel hemolysis ratio = 5% 
•  For the pure hydrogel hemolysis ratio = 12% 
+	Ve	Control	
Composite	hydrogel	 Pure	hydrogel	 -Ve	Control	
Drug loading efficiency 
Drug loading (DL) % (mg per gm of the hydrogel) = ​​𝑾↓𝒅 − ​𝑾↓𝒊 /​𝑾↓𝒊   𝑿 𝟏𝟎𝟎 
Wd = Weight of fully swelled hydrogel in drug solution (1 mg/ml). 
Wi = Weight of dry hydrogel.  
Maximum starch 
content 
Maximum MBA 
content 
Drug release study 
Drug release study at (a) different starch loading, (b) different crosslinker 
loading and respective (c & d) Korsmeyer–Peppas model fitting. (e) UV-vis 
spectra of pure and released drug. (f) Chemical structure of ciprofloxacin drug. 
F(D) = ​​𝑴↓𝑫𝒕 /​𝑴↓𝑫𝒆  = ​𝑲↓𝑲𝑷 ​𝒕↑𝒏  
Drug release% = ​​W↓drug − ​W↓release /​W↓release   𝑋 100 
MDt = Amount of drug      
release at t time;  
MDe = Amount od drug 
release at equilibrium 
condition;  
“n” = Diffusion exponent;  
In our case “n” in avg. = 
0.456 
 Polymer-Peptide Conjugate Material via CRP & 
Thiol-ene Reaction 
Ø  Polymer-Peptide hybrid materials are useful 
Ø  Drug delivery 
Ø  Substrates for Cell Adhesion  &  Recognition of certain 
proteins  
Ø   Medical applications (treatment of different diseases) . 
Ø  Elastin is a protein available in mammalian tissues, like in 
skin, lungs, ligaments. Its primary structure has repeating 
pentapeptide, VPGVG (V = valine, P = proline, G = glycine) 
Ø  Polymers with Elastin based side chain have important 
applications, like smart materials etc.  
Peptide-Polymer Conjugate via Tandem “Ester-Amide / 
Thiol-Ene”  Post-Polymerization Modification of PPFMA 
Peptide = -CVPGVG (C = Cysteine, V = Valine, P = Proline; G =  Glycine  
 Biomacromolecules 2011, 12, 2908 
H2N
OH
O
SH
Cysteine 
Polymer-peptide conjugate via Tandem Post-
polymerization  Modification 
 Biomacromolecules 2011, 12, 2908 
Ø   From the swelling study it was observed that swelling ratio of the hydrogel in 
acidic medium is lower than swelling in pH = 7.4 which is attributed due to 
presence of H-bonding in acidic condition between the carboxylic groups which 
increase the cross linking density of the gel.  
Ø  From the antimicrobial study it can be observed that presence of quaternary 
ammonium ion group in the hydrogel effectively destroy both the gram positive 
and gram negative bacteria. 
Ø  From blood compatibility study it is observed that, synthesized hydrogel is very 
much blood compatible. 
Ø  From drug release study it is observed that presence of starch  sustained the 
release of drug from the bulk of hydrogel. 
Ø   Successful “Click Chemistry” of Diels Alder reaction was carried out to 
demonstrate thermoreversible self-healing properties.  
Ø   ATRP  & Thiol-ene Reaction were successfully used to prepare Peptide-Polymer 
Conjugate.  
Conclusions 
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Ocular Pathogens: Challenges beyond bacteria 
 Savitri Sharma, MD, FAMS 
L V Prasad Eye Institute  
Hyderabad  
India 
l  Corneal blindness accounts for 15.4% of 
blindness in India (Lancet1998) 
l  Incidence of corneal ulceration is 11.3/10,000 
population in south India (Whitcher et al. Br J 
Ophthalmol, 1997) 
l  Microbial keratitis:  
–  Bacterial 
–  Fungal 
–  Parasitic 
–  Viral 
Relevant to this meeting 
•  Fungal/Mycotic Keratitis: 
Ø  Treated with antifungal antibiotics 
Ø  Poor response to medical 
treatment  
Ø  Antifungal resistance not well 
studied 
Ø  Effective drugs and drug delivery 
systems required 
•  Parasitic infections that need 
more effective drugs 
India1 
(434) 
Nepal2 
(405) 
Ghana3 
(290) 
USA4 
(663) 
Australia5 
(291) 
LVPEI6 
(5,897) 
Culture +ve 297 324 146 371 112 3,563 
Bacteria (%) 47.1 79.0 24.7 64.2 90.2 51.9 
Fungi (%) 46.8   8.4 71.9 35.8   6.2 38.2 
Mixed (%)   5.1 12.6   2.7 ---   ---   7.5 
Acanthamoeba (%)   1.0 ---   0.7 ---  3.6   2.4 
Microsporidia(%) 0.4 
1.  Srinivasan M,  et al.  Br J Ophthalmol 1997; 81: 965-971. 
2.  Upadhyay MP,  et al.  Am J Ophthalmol 1991; 111: 92-99. 
3.  Leck AK,  et al.  Br J Ophthalmol 2002; 86: 1211-1215. 
4.  Liesegang TJ,  et al.  Am J Ophthalmol 1980; 90: 38-47. 
5.  Keay L,  et al.  Ophthalmology 2006; 113: 109-116.  
6.  Gopinathan U, et al. Indian J Ophthalmol 2009; 57: 273-279. 
Reported Prevalence of Keratitis 
Organisms India1 Nepal2 Ghana3 USA4 Australia5 LVPEI6 
Moulds (%) 100 86.8 98.5 33 61 99.2 
Aspergillus (%) 16.1 47.0 15.3 12 17.1 28.9 
Fusarium (%) 47.1 11.7 52.3 --- 14.3 35.6 
Yeast (%) --- 13.2   1.5   67 39   0.8 
1.  Srinivasan M, et al. Br J Ophthalmol 1997; 81: 965-971. 
2.  Upadhyay MP, et al.  Am J Ophthalmol 1991; 111: 92-99. 
3.  Leck AK,  et al.  Br J Ophthalmol 2002; 86: 1211-1215. 
4.  Ritterband DC,  et al.  Cornea 2006; 25: 264-267. 
5.  Bhartiya P,  et al.  Clin Experiment Ophthalmol 2007; 35: 124-130. 
6.  Gopinathan U, et al. Indian J Ophthalmol 2009; 57: 273-279.  
Distribution of species of fungi in Fungal Keratitis 
Tropical areas - filamentous fungi 
Temperate zones - Yeast 
Fungal species  No.  (%) 
Hyaline  1133  (83.3)   
Fusarium spp.  506  (37.2)   
Aspergillus spp.  417  (30.7)   
Acremonium spp.  12  (0.9)   
Chrysosporium spp.  5  (0.4)   
Rhizopus spp.  1  (0.1)   
Unidentified hyaline  192  (14.1) 
Mycotic Keratitis, n=1352 
Gopinathan U, et al. Indian J Ophthalmol 2009; 57(4): 273-279 
Fungal species  No  (%) 
Dematiaceous  218  (16) 
Curvularia spp.  39  (2.8) 
Bipolaris spp.  15  (1.1) 
Exserohilum spp.   1  (0.8) 
Lasiodiplodia spp.  7  (0.5) 
Cladosporium spp.  6  (0.4) 
Scedosporium spp.  5  (0.4) 
Alternaria spp.  4  (0.3) 
Unidentified dematiaceous  124  (9.5) 
Yeast  9  (0.7) 
Mycotic Keratitis, n=1352 
Gopinathan U, Sharma S, et al. Indian J Ophthalmol 2009; 57(4): 273-279 
Bipolaris spicifera
• Title: Conidia and conidiophore
• Disease(s):    Phaeohyphomycosis
• Legend: Conidia developing from a sympodial developing conidiophore. Potato glucose agar, 630X.
• Genus/Species: Bipolaris spicifera
• Image Type: Microscopic Morphologyh
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Bipolaris spicifera 
Curvularia lunata 
•  Simple laboratory tests such as 
microscopic examination of 
corneal scrapings and culture are 
highly sensitive (>90%) for 
diagnosis.  
  Calcofluor white stain 
  Gram stain 
•  Culture on  blood agar, Sabouraud 
dextrose agar. 
Laboratory Diagnosis of Fungal Keratitis 
Confocal Microscopy 
(In vivo diagnosis) 
Vadavalli  et al. Ophthalmology2011;118:29 
Medical Therapy - Antifungal Drugs 
Topical 
•  Polyenes – Amphotericin B (0.15%), Natamycin (5%) 
•  Azoles – Fluconazole, Itraconazole, Voriconazole, 
econazole (2%) 
•  Flucytosine 
Systemic - Azoles, Amphotericin B, Echinocandins 
Combination therapy of Azoles and Polyenes 
Limitations 
•  Fungistatic nature 
•  Narrow spectrum  
•  Poor penetration 
•  Toxicity 
•  No conclusive advantage of one 
over another-Contradictory results 
•  Limited information on antifungal 
susceptibility of ocular isolates  
Antifungal Drugs 
•  * 43 Fusarium spp: MIC 90 
  Ampho B   -  2 µg/ml 
   Natamycin  -  4 
   Miconazole  - >32 
   Itraconazole  - >32 
   Flucytosine  - >512 
•  @ Natamycin eye drops usage for MIC 
In vitro Antifungal Susceptibility 
* Reuben et al. antimicrob agents chemother1989;33:1647 
@ Lalitha et al. J clin Microbiol 2008;46:3477  
@  Pradhan et al. Indian J Ophthalmol 2011(In Press) 
 
CLSI guidelines not available for many antifungal antibiotics 
•  * 112 patients- 2% econazole Vs 5% natamycin 
•  No difference in outcome. Equally effective 
•  @  120 patients - 1% voriconazole Vs 5% natamycin 
•   No difference in outcome at 3 months. 
•  Voriconazole: 
Ø  Excellent penetration in deeper layers of cornea 
Ø  Soluble drug- anecdotal reports of intracorneal 
injection with good outcome. 
Antifungal drugs for fungal keratitis - RCT 
(Inconsistent with in vitro results) 
* Prajna et al. Br J Ophthalmol 2003;87::1235 
@ Prajna et al. Arch Ophthalmol 2010;128:672 
 
Cochrane review  
•  12 randomised trials 
•  981 subjects randomized 
•  Eight antifungal drugs studied 
•  All trials done in developing nations 
•  Variable quality and underpowered 
•  No good evidence for most comparisons 
except Natamycin and Voriconazole 
Fungal Keratitis Management 
Natamycin v/s Voriconazole 
Fungal Keratitis 
Outcome Arora et al 2011 MUTT 2013 Prajna et al 2010 
Clinical 
cure 
Nata 
N=15 
Vori 
N=15 
 
Nata 
N=162 
 
Vori 
N=161 
 
Nata 
N=60 
 
Vori 
N=60 
Number 
(%) 
15 
(100) 
14 
(93.3) 
NR NR NR NR 
Microbiolo
gy cure 
Nata 
N=15 
Vori 
N=15 
Nata 
N=155 
Vori 
N=143 
Nata 
N=60 
Vori 
N=60 
Number 
(%) 
NA NA 132 
(85.2) 
75 (52.1) NA NA 
Fungal Keratitis Management 
Fungal Keratitis 
•  Voriconazole inferior  
to Natamycin against 
Fusarium keratitis 
•  Both drugs equally 
effective against 
Aspergillus keratitis 
Fungal 
species 
 
MIC 90 (µg/mL) 
 
Amphote
ricin B 
Voriconaz
ole 
Fluconazol
e 
Natamyci
n 
Caspofun
gin 
Itraconazol
e 
C albicans 0.25 0.125 3.0 8 0.38 2 
C 
parapsilosis 
0.50 0.5 24.0 4 0.75 3 
Challenges 
•  Paucity of clinical trials 
•  Lack of interest in academia and 
industry 
•  Lack of experience with majority of 
antifungal agents 
•  Poor correlation with in-vitro activity 
Fungal Keratitis 
Medical Management 
•  * Occasional Reports of response of fungal keratitis 
to fluoroquinolones. 
•  @  Susceptibility of Fusarium and Aspergillus tested  
   
Antifungal  activity of antibacterial  
antibiotics and preservatives 
* Khor et al. JAMA 2006;295:2867 
* Munir et al. Cornea 2007;26:621 
@ Day et al.Br J Ophthalmol 2009;93:116 
Amox Cefaz Chloram Moxi Tobra Benz 
Fusarium 
spp. 
>4000 >4000 2000 2000 700 64 
Aspergillus 
spp. 
>4000 >4000 4000 >4000 >4000 16 
MIC 90- µg/ml 
Many	  of	  the	  fungi	  grown	  from	  clinical	  samples	  remain	  
uniden6ﬁed	  due	  to	  lack	  of	  spores.	  
Gopinathan et al., Cornea 2002; 21(6): 555-559. 
Srinivasn M. Current Opinion in Ophthalmology 2004; 15:321-327.  
Inves6ga6on	  into	  hidden	  (non-­‐sporula6ng)	  fungi	  
	  
•  Large	  number	  of	  ITS	  copies	  per	  cell	  (up	  to	  250)	  makes	  the	  region	  an	  appealing	  
target	  for	  sequencing	  samples.	  
•  The	  en6re	  ITS	  region	  ranges	  between	  450	  and	  700	  bp.	  
•  Helps	  to	  ﬁnd	  previously	  unknown	  species.	  
 Pythium insidiosum isolate 297 (AY151170.1) 
 Pythium insidiosum B521/11 
 Pythium insidiosum isolate 296 (AY151169.1) 
 Pythium insidiosum isolate M16 (AY151166.1) 
 Pythium insidiosum isolate 394 (AY151163.1) 
 Pythium insidiosum isolate 65 (AY151157.1) 
 Pythium destruens isolate M24 (AY151175.1) 
 Pythium insidiosum isolate M20 (AY151167.1) 
 Pythium insidiosum isolate M22 (AY151168.1) 
 Pythium insidiosum H1778/09 
 Pythium insidiosum CBS 574.85T (AY598637.1) 
 Pythium insidiosum B1915/10 
 Pythium insidiosum isolate CM01 (EF016856.1) 
 Pythium insidiosum B2023/10 
 Pythium insidiosum B39/11 
 Pythium insidiosum B512/11 
 Pythium insidiosum B654/11(2) 
 Pythium insidiosum B634/11 
 Pythium insidiosum B515/11 
 Pythium insidiosum isolate M18 (AY151178.1) 
 Pythium insidiosum isolate 291 (AY151176.1) 
 Pythium insidiosum H242/14 
 Pythium grandisporangium isolate 54 (AY151182.1) 
 Pythium aphanidermatum isolate 135 (AY151180.1) 
 Pythium deliense isolate 66 (AY151181.1) 
 Lagenidium giganteum isolate 36492(AY151183.1) 
 Phytophthora megasperma isolate EP1 (L41381.1) 
99 
99 
88 
96 
68 
99 
99 
66 
0.05 
Broad, aseptate fungal filaments  
with ribbon-like folds 
 (KOH+CFW, x400) 
Colourless, flat, appressed fungal  
colony with feathery edges  
(Blood agar, 4 days growth at 37oC)  
Report of 9 cases in 2010-12 (9/162, 5.5%); 4 cases in 2014 (4/102, 3.9%)  
Sharma et al. Pythium insidiosum keratitis: Clinical profile and role of  DNA  
sequencing and zoospore formation in diagnosis. Cornea 2015;34:438-442 
Inferior stromal infiltrates with 
multiple linear tentacle-like infiltrates 
extending from superior edge of the 
limbus 
Dry, full thickness infiltrates with 
hyphate edges and multiple dot-like 
infiltrates surrounding the main 
infiltrate 
Clinical Presentation of Pythium keratitis 
Poor response to topical natamycin therapy 
 L V Prasad Eye Institute- Hyderabad data- 2014 
(Pythium insidiosm keratitis- n=37) 
•  Prevalence- 37/728 (5%) fungal keratitis patients 
•  Mean age: 38.3+ 13.8 years (range: 12-68 years) 
•  Males-17, Females-20 
•  Predisposing factors- trauma-15, none-22 
•  Dot like infiltrates-20, tentacles-6, ring infiltrate-6, plaque-6 
•  Corneal perforation -1 
•  Treatment- Topical natamycin, systemic antifungal-36, 
Intrastromal voriconazole-5, Collagen cross linking-1  
•  PK- 33, Recurrence after PK-8, failed graft-16 
•  Superficial keratectomy  
•  Tissue adhesive 
•  Lamellar Keratoplasty 
•  Penetrating Keratoplasty 
Surgical options for non-
responding fungal keratitis 
•  Long term medications 
•  Expensive 
•  Recurrence 
•  Graft Failure/Rejection 
•  Graft infections  
Consequences of keratoplasty 
Efforts need to continue towards better medical 
therapy in fungal keratitis  
Protozoa    Helminths            Arthropods 
            _____________________________________________ 
              Nematodes            Cestodes             Trematodes 
__________________________________________________ ______________________________ 
Toxoplasmosis       Toxocariasis  Cysticercosis   Schistosomiasis        Ophthalmomyiasis 
Acanthamoebiasis   Ascariasis   Echinococcosis  Paragonimiasis 
Entamoebiasis        Onchocerciasis                      Coenurosis 
Malaria                    Loiasis                                    Sparganosis 
Giardiasis                Dirofilariasis 
Leishmaniasis         Filariasis 
Trypanosomiasis    Dracunculiasis 
Pneumocystosis     Thelaziasis 
Microsporidiosis     Gnathostomiasis 
                                Angiostrongyliasis 
                                 Trichinosis 
 Parasites causing eye infections 
•  Ubiquitous free living amoebae 
•  Chronic granulomatous 
encephalitis 
•  Keratitis 
 Inflammation of cornea 
 Significant monocular morbidity 
 First case diagnosed in 1973 
 In India - Madurai - 1987   
•  Disseminated cutaneous infection 
in AIDS patients 
Acanthamoeba 
•  Acanthamoeba infection can mimic all types of 
keratitis: viral, bacterial or fungal 
•  It is frequently misdiagnosed as herpes simplex 
keratitis 
•  Mistakenly reported to be fungal keratitis in as 
high as 45% of the cases 
Sharma S, Garg P, Rao GN. Patient characteristics, diagnosis and treatment of non-contact lens related 
Acanthamoeba keratitis. Br J Ophthalmol. 2000;84:1103–1108 
         Acanthamoeba Keratitis 
Acanthamoeba keratitis 
Conventional methods of diagnosis 
(Pasricha et al. J Clin Microbiol 2003) 
Total
+ - + - + -
Culture + 118 17 109 26 95 40 135 (81%)
Culture - 29 2 26 5 27 4 31
Total 147 (89%) 19 135 (81%) 31 122 (73%) 44 166
KOH/CFW Gram Giemsa
Medical management 
•  Biguanides – Chlorhexidine 0.02%  
                       PHMB 0.02% to 0.06% 
•  Diamidines – Propamidine isethionate 0.1% 
                       Hexamidine 0.1% 
 
         Acanthamoeba Keratitis 
Surgical management   
•  Epithelial debridement  
•  Amniotic membrane transplantation 
•  Lamellar keratectomy combined with conjunctival flap 
•  Phototherapeutic keratectomy 
•  Penetrating keratoplasty 
•  Deep lamellar keratoplasty 
•  Sharma S, Garg P, Rao GN. Patient characteristics, diagnosis and treatment of non-contact 
lens related Acanthamoeba keratitis. Br J Ophthalmol. 2000;84:1103–1108 
•  Parthasarathy A, Tan DT. Deep lamellar keratoplasty for Acanthamoeba keratitis. Cornea. 
2007;26:1021–1023 
         Acanthamoeba Keratitis 
Surgical treatment required by approximately 5-10% patients   
Microsporidial infections of the eye 
 
•  Anecdotal reports in AIDS patients in 1990s 
•  Case reports of superficial keratoconjunctivitis in 
immunocompetent patients 
  Lewis NL et al. Cornea 2003 : 374-6 
  Moon SJ et al.  Cornea  2003 : 271-2 
•  Ist report from India in 2003 
  Sridhar MS, Sharma S. AJO 2003 : 745-6 
 
   
 (Routine smear examination of corneal scraping) 
KOH+CFW, Gram stain, 1% AFS 
 Joseph et al. J Clin Microbiol 2006, 44:4 
Diagnosis & Clinical Features 
•  January 2002- December 2004, LVPEI-Hyderabad 
•  19 patients of microsporidial keratoconjunctivitis 
Diagnosis, clinical features and treatment outcome of microsporidial 
keratoconjunctivitis 
Sujata Das, Savitri Sharma, Srikant K Sahu, Shyam S Nayak, Sarita Kar 
Br J Ophthalmol 2012;96:793e795. doi:10.1136/bjophthalmol-2011-301227 
•  March 2007-Oct 2010, LVPEI-Bhubaneswar 
•  270 patients of microsporidial keratoconjunctivitis 
•  Seasonal, diagnosed by simple lab. test, outcome satisfatory 
Clinical Trial of 0.02% Polyhexamethylene 
Biguanide Versus Placebo in the Treatment of 
Microsporidial Keratoconjunctivitis 
SUJATA DAS, SRIKANT K. SAHU, SAVITRI SHARMA, SHYAM SUNDAR 
NAYAK, AND SARITA KAR 
Am J Ophthalmol 2010;150:110–115 
Treatment of Microsporidial 
Keratoconjunctivitis 
CONCLUSIONS: Treatment of microsporidial 
keratoconjunctivitis with PHMB does not offer any 
significant advantage over placebo, suggesting self-
limiting nature of the disease. 
Microsporidial Stromal Keratitis 
•  Five cases with DD -  HSV /fungal/bacterial 
keratitis 
•  Steroids worsened the condition. 
•  Spores not seen beyond Descemet‘s membrane in 
any case.  
•  Lack of effective medical therapy 
•   surgical treatment required 
Microsporidial Stromal Keratitis 
Intraocular Invasion by 
Microsporidial Spores 
in a Case of Stromal 
Keratitis. 
S Das, Sharma S, Sahu SK, 
Vemuganti GK 
Arch Ophthalmol/vol 129 (no. 4), 
Apr 2011 
Currently 34 cases of stromal keratitis 
 
•  Fumagillin 
•  Albendazole 
•  Fluoroquinolones- Ciprofloxacin 
•  Biguanides- Chlorhexidine, PHMB 
Microsporidial Stromal Keratitis 
Medical Management 
Poor response to medical management.  
Keratoplasty is the rule rather than exception. 
Summary 
•  Fungal/Parasitic Keratitis: 
Ø  Suboptimal response to medical treatment 
Ø  Antimicrobial resistance not well studied 
Ø  More effective drugs and drug delivery 
systems required 
 
 
 
 
Vijaya Gopal 
CSIR-Centre for Cellular & Molecular Biology 
 Hyderabad  
UK-India DBT-MRC workshop, 14-15 March 2016 
 
 
 
 
 
Silencing Protease Targets in the Brain:  
Implications for Therapy of Alzheimer’s Disease 
Nucleic Acid Delivery 
 
 I RNAi therapeutics targeting neurodegenerative diseases 
 II Targeting HER2+ ovarian and breast cancer 
 III Development of multifunctional AuNP platforms for the co-delivery of 
 nucleic acids and drugs   
 IV  Structure-function activity of derivatized tocopherol-based formulations 
 V Lipid/peptide-mediated gene delivery 
Nucleic Acid Delivery 
Systemic                          Local 
Intracellular  
Barriers 
Nuclear 
Barriers 
 
Signaling 
effects 
  
 
Biological 
effects 
  
Enzymatic/Serum 
Peptide-guided gene delivery.  
Martin & Rice, AAPS J. (2007) 
 
Nature as a source of inspiration for cationic 
lipid synthesis.  
Labas et al. Genetica (2010) 
 
Peptides in DNA delivery: current insights  
and future directions. Mann et al. Drug Discov 
Today (2008) 
 
Cationic liposomal lipids: From gene carriers 
to cell signaling. Lonez et al. Progress in  Lipid 
Research  (2008) 
 
Rao & Gopal Cationic lipids for gene delivery 
in vitro and in vivo. Expert Opinion on 
Therapeutic Patents (2006)  
 
Gopal, V Bioinspired peptides as versatile 
nucleic acid delivery platforms  J Control 
Release (2013) 
 
RNAi works via delivery of small RNA duplexes, including microRNA (miRNA) 
mimics, short interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), and 
Dicer substrate RNAs (dsiRNAs) 
• dsiRNA-Dicer processing  
• shRNA-nuclear processing 
• siRNA and miRNA mimic pathways are the most direct (delivery to RISC 
loading) 
• Unlike siRNAs, miRNAs are not 100% complementary to target sequences 
 
Major considerations: Toxicity, Efficacy and Delivery  
The promise of RNA Interference (RNAi)-Based Therapeutics 
 
Key therapeutic advantages of RNAi 
 
 Presence of RNAi machinery in mammalian cells 
 High specificity and ability to evade drug resistance 
 Potential of designing siRNA to any disease causing gene 
Modular Structure of dsRNA binding proteins 
FASEB J (2003); Nat. Rev. Cell Biol. (2004) 
TRBP has higher affinity towards  
shorter dsRNA 
Design and expression of recombinant fusion protein TRAF 
M.W = 18.6kDa 
Selective accumulation of (TRAF:siRNA) into HER2+ tumor tissues 
Systemic delivery of TRAF:siRNA complex led to significant suppression 
of tumor growth in xenograft mice 
Dar et al. Nanomedicine (2015) 
 • Accumulation of amyloid-b is a major signature of Alzheimer’s disease  (AD).  
 
• Formation of amyloid-b is catalyzed by g-secretase, a protease with numerous 
substrates. 
 
• Existing drugs for clinically effective g-secretase inhibitors are toxic/mask 
symptoms but do not halt disease progression. Besides, these interfere with 
cellular homeostasis/are pumped out resulting in low efficacy and failures. 
(Svedruzik et al. PLOS ONE-8, 2013, Mangialasche et al. Lancet Neurol. 9, 2010, He 
et al. Nature, 2010).  
 
• Key insights into molecular mechanism behind this complex disease is still being 
investigated to arrive at suitable therapeutic strategies. Targeting the enzyme 
complex, at the molecular level, to inhibit Ab peptide production using RNA 
interference (RNAi) is potentially an attractive strategy for therapeutic 
intervention.  
  
• However, the lack of efficient delivery systems is currently the bottleneck 
for clinical application of RNAi. 
Aβ Generation 
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- 
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C 
Lumen 
Cytosol 
b-amyloid precursor protein 
APP 
Aβ Generation 
 
BACE1 initiates Aβ generation - a prime drug target for lowering cerebral Aβ levels in 
the treatment and/or prevention of AD 
Generation 
Key targets: g and b-
secretases;  
a-secretase 
Toxicity 
(Possible targets: 
M1, mGluR5, 
RAGE,p75 etc.) 
Accumulation 
(Key approaches: 
Active/passive 
immunotherapy; 
disaggregators; 
degradation enzymes; 
efflux/influx) 
Various approaches targeting Ab 
Reduce pathogenic Ab 
 
Combinatorial therapy 
• Several approved drugs that reduce Aβ peptide by targeting g-secretase also affect Notch 
processing, making them either toxic/less effective. Lack of specificity and weak potency of 
inhibitors has slowed down the development of promising drug candidates to this target. 
 
• The discovery of a g-secretase activating protein (GSAP) that controls Aβ  production suggests a 
potential and new molecular target that involves both g-secretase and its substrate, the amyloid 
precursor protein C-terminal fragment (APP-CTF).  
 
• Reducing GSAP was shown to decrease amyloid-b without affecting other key functions of g-
secretase. 
(He et al. Nature 467, 95-98 2010) 
Pathways for transport across the blood-brain barrier 
Adapted from Abbott et al. Nature Reviews|Neuroscience (2006) 
 
   b-Secretase (BACE 1) Lentiviral vector Singer et al. Nature Neuro. 2005 
  Acetylcholine receptor RVG-9R Kumar et al. Nature, 2007 
  g-secretase activating protein Therapeutic target He et al. Nature,  467, 2010 
   b-Secretase (BACE1) via GM1 TARBP-BTP (13.5kDa) Haroon et al. J Controlled Release 2016 
  
• More than 90 drugs are in various stages of clinical trials.  
 
• NIH-Clinical trials - 1426 studies for Alzheimer’s disease  
 
• Gantenerumab, Memantine, Rivastigmine , NIC5-15, Varenicline, Donepezil, TRx0237, 
Interferon beta-1a, LY450139, ELND005, DAPT.  
http://www.clinicaltrials.gov/ct2/results?term=alzheimers&Search=Search 
 
• Status of vectors for receptor-mediated transcytosis to improve delivery of peptides into the 
brain: Cationized albumin, transferrin, liposomes, mAbs to transferrin receptor, BDNF-OX26. 
Angiopep-2 peptide conjugated to paclitaxel- derived from ligands that bind LRP-1 highly 
expressed in the brain endothelial cells, neurons and astrocytes. T. J. Siahaan (Handbook of 
biologically active peptides - 2013). 
 
 Viable neurons are targets for therapeutic intervention of AD 
Current status for all RNAi-based therapies - 35 studies 
 
In Alzheimer’s disease, increased b-secretase(BACE1) activity has been associated with 
neurodegeneration and accumulation of amyloid precursor protein (APP) products. 
Inactivation of BACE1 could be important in the treatment of Alzheimer’s disease. 
Determination of GM1 levels  
Alexa Fluor647-CTB 
Construct design and in vitro analysis  
of TARBP-BTP fusion protein  
                Uptake of TARBP-BTP: siRNA complex
   
TARBP-BTP mediated recognition of Ganglioside GM1 
TARBP: siRNA 
 
Carrier w/o the  
targeting ligand 
TARBP-BTP recognizes ganglioside GM1 
TARBP-BTP mediated  
 knockdown of BACE1 
 
41% 
TARBP-BTP fusion protein is non-toxic 
Biodistribution of TARBP-BTP complex in AbPP-PS1 mouse brain 
Target specificity 
Localization of TARBP-BTP complex in the brain 
Silencing of endogenous GAPDH 
40% 
TARBP-BTP mediates RNAi of GAPDH in the hippocampus and cortical regions 
TARBP-BTP-mediated gene silencing of BACE1 in  
ΑPPswe-PS1dE9 (ΑβPP-PS1) AD mouse model  
Targeted delivery of BACE1 siRNA results in 30-50% reduction in BACE1 expression 
Haroon et al. J Controlled Release (2016)  
A promising therapeutic approach towards treating neurodegenerative diseases! 
 
Outcome of a combinatorial therapy targeting GSAP and BACE1? 
Reduction in Ab levels? 
Universal non-viral RNAi delivery systems for Ocular Diseases 
Targeted manipulation of gene expression 
 RNAi is promising and rapidly moving in the translational research space. 
 
 The specificity of silencing virtually any gene by design of peptide-based 
delivery systems may offer the possibility of surpassing limitations of the 
BAB/BRB to deliver siRNA without side effects.  
 
 Alternative to issues pertaining to drug resistance  
• Duvvuri  et al. Expert Opin Biol Ther 2003, 3: 45-56 
• Del Amo EM, Urtti ADrug DiscovToday 2008, 13: 135-143. 
• Li et al. Diagn Pathol. 2009; 4: 46. 
• Thakur et al. Journal of Biological Engineering20126:7 
• Reischl and Zimmer, Nanomedicine: Nanotechnology, Biology and Medicine 2009, 
5: 8-20.  
• Bobbin & John Rossi, Annu. Rev. Pharmacol. Toxicol. 2016. 56:103–22  
 
The potential for RNAi therapeutics is limited by delivery technology  
 Future scope 
 
• Ocular disease is an easy target for RNA-based therapeutics.  
• Disease targets and RNAi drug candidates in clinical trials  
 
Approved RNA therapeutics 
-Macugen –Targets VEGF in the eye 
Other targets include the B2 adrenergic receptor, RTP801, and TRPV1.  
Bevasiranib (NCT00499590), an anti- VEGF siRNA therapy for wet macular degeneration was 
discontinued during Phase III trials  
 
-SYL040012, or bamosiran, is the second RNAi therapeutic that Sylentis has in clinical 
development. This RNAi therapeutic is currently in a Phase IIb clinical trial for patients with 
glaucoma, ocular hypertension, or open-angle glaucoma.  
 
-Caspase-2, a protein involved in apoptosis to reduce retinal ganglion apoptosis  
These diseases are caused by degeneration of the optic nerve, which leads to irreversible visual 
field loss  
 
Future challenges should encompass strategies for delivery to less accessible 
areas to limit off-target effects 
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Morphology, Stability, Porosity, Diffusion, 
Release, Enzyme, pH
Core
Process 
Modeling
Multi-scale 
Processes
Controlled 
Release
Molecular 
Thermodynamics 
& Coarse Graining
Catalysis
Molecular 
Dynamics
Materials
Nano-Bio
Optimal Control
Multiscale Modeling
• Thermodynamics, Liquid Models, Coarse Graining 
(CG), Molecular Modeling, Dissipative Particle 
Dynamics -DPD
Lignin to BTX/ Lower Phenolics
•Lignin, Degradation, Catalysis, BTX, Lower 
Phenolics, Kinetics, Solvent, Liquid Products 
Dr. C S Sharma, IITH
Dr. K Mitra, IITH
Dr. D Shee, IITH
Dr. D Chaudhuri, IOP
Prof. P Ray, CU
Gelatin Casted Thin-Film Based DDS
Materials and Manufacturing Processes, 2016, 31, 223-230
Anindita, Ph.D Student
Controlled Drug Delivery: Nano-fiber DDS
Gelatin 
Nanofiber
Electrospun
Crosslinking
Long and 
uniform 
fibers with 
diameter 
range 
50nm to 
200nm 
Stability in 
low pH
Slow to fast 
release: 
High to Low 
crosslinking 
Anindita, Ph.D Student
RSC Best Poster: 
Macro 15
Biochemical Engineering Journal, 2015, 105, 481
Controlled Drug Delivery: Hydrogel DDS
Drug release study of 60/40 NC/LV/ HV 
and hybrid samples in pH 7.4 and pH 1.2
(a) 70/30 HV-NC (b) 70/30 HV 0.2% GTA 
(c) 70/30 hybrid-NC (d) 60/40 hybrid-NC
60/40/NC/hybrid pH 7.4 vs 
60/40/NC/hybrid pH 1.2
Utkarsh, Ph.D Student
Materials Letters, 2016, 164, 76–79
Comparison between flux data of Kontturi et. al. 
(1998) and simulation results for step-wise 
(voltage induced) release of salicylate molecules
Conducting Polymer Based DDS
• CHEMPHYSCHEM, Vol. 11, Page 211-219
• Polymer Engineering & Science, Vol. 51, No, 
10, Page 2001-2012
Pinaki, Ph.D Student
Coarse grained molecular dynamics 
• Accessing length scale and time scale that classical MD can not reach
• Application to polymers under confinement
Work in Progress
Multi-scale Modeling: Coarse Graining
Guo et. al., Soft Matter, 2012
Multi-scale Modeling: Interfacial Tensions (DPD Application)
RakeshHimanshu
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Molecular Dynamics DPD
How to approximate the bead size and 
property in predictive fashion? 
Can we reduce some assumption?
Is it better to use different experimental (or 
MD) findings for parametrization? 
*
Thermostat 
that Respects 
Hydrodynamics 
**
Higher Length 
& Tine Scales **
* Relation with 
Stat. Mech. & 
Exp. Findings
Chem. Phys. Lett. 600, 62 (2014)
Drug & Polymer
- Mat. Characterization
- Drug-Poly Conjugate
- Stability, Degradation
Fundamentals
- Molecular Simulations & Properties
- Drug-Poly Compatibility & Solubility
- Polymer Relaxation, Diffusion, Interaction
In Vivo
- Cell line study
- Real conditions
- Animal Study
Bird’s Eye View
Solubility Parameter
Hydrogel
FOCUS OF THE DAY
Utkarsh, Research Scholar
GYTI Award 2016
Drug Delivery Systems (DDS): Relevance & Encapsulation
• Cost of vehicle
• Natural/ widely accepted material
• High porosity & natural networks
• Stable under lower pH and enzymes
http://www.ijp-online.com/articles/2011/43/4/images/Indian%20J%20Pharmacol_2011_43_4_409_83111_f2.jpg
Soya Nuggets
Soya Nuggets – A Potential Carrier: Swelling Kinetics and Release of Hydrophobic Drugs
Characteristics of  Polymeric Cargo
Swelling
Biodegradable
Drug Encapsulation
Control Release
Swells
Bio-
degradable
Porous
Protein 
Rich
Widely 
Accepted
Lets find out if it acts as a successful cargo
A STEP BY STEP APPROACH…
Why the nuggets swelled more in pH 1.2??
Was there any degradation observed??
𝑆𝐷 % =
𝑊𝑠 −𝑊𝑑
𝑊𝑑
𝑋 100
First Roadblock 
Difficulty to Opportunity: Load the drug in low pH (i.e. 25/75 HCl/Ethanol)
200µm 10 µm
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𝐿𝐸 (%) =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛𝑠𝑖𝑑𝑒 𝑡ℎ𝑒 𝑛𝑢𝑔𝑔𝑒𝑡
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
𝑋 100 Storage and Loss Modulus
• Higher nugget wt. higher storage & loss modulus.
• Higher modulus, lesser tendency to swell. That’s
why, higher weight nugget swelled less.• LE of Piperine increases and then decreases. Same
trend was observed during porosity measurements.
Second Roadblock 
Swelling of soya nuggets considered to be second order and the 
swelling rate at particular time interval expressed as 
𝑑𝑊
𝑑𝑡
= 𝐾 𝑊∞ −𝑊
2
Integrating the above equation between t=0 and W=0,
𝑊 =
𝐾 𝑊∞
2𝑡
1 + 𝐾𝑊∞𝑡
Rearranging above equation:
𝑡
𝑊
=
1
𝐾 𝑊∞ 2
+
𝑡
𝑊∞
SWELLING KINETICS
𝑴𝒕
𝑴∞
= 𝑲 𝒕𝒏
Sample/pH Time (min) n Type of diffusion
Pure soya/7.4 60 0.18 Less Fickian
Pure soya/1.2 60 0.17 Less Fickian
1%SA/1%CaCl2/1.2 240 0.326 Less Fickian
1%SA/2%CaCl2/1.2 240 0.313 Less Fickian
1%SA/3%CaCl2/1.2 240 0.28 Less Fickian
1%SA/5%CaCl2/1.2 240 0.24 Less Fickian
Diffusion Kinetics by Power Law
Power Law
Siepmann & Peppas, Advanced Drug Delivery Reviews 48 (2001) 139–157
Wang J, Wu W and Lin Z. Journal of Applied Polymer Science, 2008; 109: 3018 – 3023
~20% Hydrophobic Content (Fibers and Fat etc.)
Water
Polymer A
Polymer B
Polymer B: Hydrophobic
Anomalous 
Diffusion
Comparable relaxation & diffusion
Less Fickian
Faster relaxation & 
Slow diffusion
Swelling Possibilities (Schematic)
n ≈ 0.45 
n < 0.45 
1 > n > 0.45 
n ≈ 1 
• Water-Polymer Interactions
• Conformational Changes
• Diffusion
• Osmotic Pressure
Anomalous 
Diffusion
Comparable relaxation & diffusion
Release Possibilities in PBS 7.4 (Schematic)
1 > n > 0.45 
• Hydrophobic Drug (Piperine)
Fickian
Diffusion
Faster relaxation
n ≈ 0.45 
• Hydrophilic Drug (Metformin)
Sample n Type of Diffusion
Pure soya/7.4 0.57 Anomalous Transport
1% SA NC 7.4 0.59 Anomalous Transport
1%SA 5%Ca 7.4 0.65 Anomalous Transport
1%SA 2.5%Ca 7.4 0.62 Anomalous Transport
For the applicability of power law for drug release, the cumulative release
should be more than 60%. Only 4 cases satisfied the above condition.
Release Kinetics by Power Law
Sample n Type of Diffusion
1% SA 5% Ca 7.4 0.46 Fickian
Piperine
Metformin
Release Kinetics by Power Law
TILL NOW….
Increases and Then decreases with Nugget weight
Lower weight nugget swells more
Drug Loading Increases then decreases with nugget weight
Lets Check the drug release now, but before that lets see the stability of the drug and chemical interactions 
Higher the nugget weight higher the storage and loss modulus.
Higher the modulus, lesser the tendency to swell.
• Drug stability also confirmed via FT-IR analysis
• The peaks in pure soya also confirm the
presence of large number of protein groups
Soya+Piperine
KEY FEATURES OF DRUG RELEASE
Pure soya nuggets give a fast release in  pH 7.4
Soya nuggets in pH 1.2 were observed to give 
drug release of around 33% in the First 240 min.
The soya nuggets were coated and  cross-liked 
which led to a control over  the drug release.
1% SA and 5 % CaCl2 cross-linked sample was 
observed to give a better release
To further test the potential of nuggets, dual 
release of piperine and curcumin was tested.
Piperine dominated the release as it enhances 
the bioavailability of curcumin. 
The nuggets were also tested with other drugs like 
metformin, ibuprofen. 
Few parameters like concentration of SA coating and CaCl2 were also varied and studied for drug release 
1%SA/5% CaCl2 offers a better control over the release of piperine
STORAGE OF DRUG LOADED NUGGETS CONCLUSIONS
Hydrogels
Soya 
Nuggets
WHO WINS THE BATTLE???? WORK IN PROGRESS
In-Vitro Cell line study: Dr. Lopa (IITH)
Use of plasticizers for better drug 
distribution
Increasing the loading efficiency of the 
vehicle
Molecular modelling to predict the drug 
distribution: MD & DPD
Incorporating widely used drugs
Looking at any carrier from all possible aspects
Scientific Contributions in Last Year (Drug Delivery)
• Utkarsh Bhutani, Anindita Laha, Kishalay Mitra, Saptarshi Majumdar, Sodium alginate and gelatin hydrogels: Viscosity effect on
hydrophobic drug release, Materials Letters, 2016, 164, 76–79
• Utkarsh Bhutani, Saptarshi Majumdar, Soya Nuggets – A Potential Carrier: Swelling Kinetics and Release of Hydrophobic Drugs,
RSC Advances, 2015, 5, 92184-92188
• Anindita Laha, Utkarsh Bhutani, Kishalay Mitra, Saptarshi Majumdar, Fast and Slow Release: Synthesis of Gelatin Casted-Film
Based Drug Delivery System, Materials and Manufacturing Processes, 2016, 31, 223-230
• Anindita Laha, Shital Yadav, Saptarshi Majumdar, Chandra S. Sharma, In-vitro release study of hydrophobic drug using
electrospun cross-linked gelatin nanofibers, Biochemical Engineering Journal, 2015, 105, 481
Hydrogels
Natural Materials
Thin Films
Nano-Fibers
Expectation for Next Gen Oral DDS:
• High Drug Loading
• Cheap/ Min. Functionalization/ Natural Polymer
• Controlled Polymer Degradation (pH, Enzyme etc.)
• Less Toxic Chemicals (Min. Amount as well)
• Close to Zero-Order Release for ~48 Hours
• Complete Degradability of the Vehicle
Thank You
	Use	of	Ultrasound	to	enhance	
an0microbial	eﬃcacy		
	
Dr	Joey	Shepherd	
	
School	of	Clinical	Den.stry,	the	University	of	Sheﬃeld	

Overview	
•  What	is	ultrasound	(US)?		
•  US	in	an7bacterial	therapy	
•  Current	projects		
•  US	in	opthalmology	
What is ultrasound? 
•  Sound is a travelling longitudinal pressure 
wave 
•  Ultrasound = High frequency sound waves 
•  Frequency: 
–   pulses per second 
–  expressed in Hz (eg 10,000 cycles per second = 
10 kHz).  
–  Human hearing ~20 Hz-20 kHz 
–  Ultrasound = >20kHz 
  
What’s a Hz? 
•  1Hz = 1 oscillation of the sound wave per 
second 
  
•  2MHz - 10MHz medical 
 diagnostic frequency range 
•  Low frequency US  
= 20kHz – 500kHz 
Intensity 
•  Power: measured in watts (W);  
–  amount of energy being produced by the 
transducer 
 
•  Intensity: strength of sound waves at 
treatment location 
–  expressed in watts per square centimeter (W/cm2)  
–  Changing ultrasound head size affects power 
density (larger head results in lower density) 
Larger	transducer	head	
allows	for	lower	intensity	
Uses	of	US	
MEDICAL	 ANIMALS	
	
	
SHIPPING	
	
•  Cleaning	
•  Mixing	
•  CuBng/engraving	
•  Food	industry	
•  Echoloca7on:	bats,	
dolphins	
•  Frog	communica7on	
INDUSTRY	
•  Imaging/diagnos7cs	
•  Bone	fracture	repair	
•  Descalers	
	
•  Echoloca7on	of	rocks/sandbars	
•  Echoloca7on	of	schools	of	ﬁsh	
US	in	an0bacterial	therapy	
•  Low frequency, high intensity US is used 
routinely for cleaning (ultrasonic baths)		
•  Most research shows effectiveness of low 
frequency US when used in conjunction 
with antibiotics 
	
S.epidermidis,	+/-	US	+/-	75	μg/ml	
ampicillin		
70	KHz,	3W/cm2	
Rediske	et	al	
J.Gen.Appl.Microbiol	44:283		
PiT	et	al	
An2microb.Agents.Chemother.	
38:2577	
P.aeruginosa,	+/-	US	+/-	gentamicin	
67	KHz	
Sonopora0on	
US creates pores in membranes allowing 
antibiotics to get into cells (‘sonoporation’) 
	
	
US-induced	cavita0on	in	liquids:	
Low	intensity	
High	intensity	
Low	frequency	in	liquids	
	Sonopora0on	mechanisms	
for	therapeu0c	delivery	
	
(a) Sonopora0on	for	drug	delivery.	
Microbubbles	with	drug	aTached	to	the	
surface	or	enclosed	within	the	par7cle	
travel	in	capillaries.	Upon	US	exposure	
MBs	rupture,	releasing	the	drug	contents.	
Drugs	are	absorbed	by	the	target	7ssue.	
(b) 	Sonopora0on	for	gene	delivery.	plasmid-
DNA-(pDNA-)	containing	MBs	are	passed	
through	blood	vessels	adjacent	to	tumor	
cells,	US	waves	rupture	MB	and	release	
pDNA.	Released	pDNA	penetrates	into	
cells	through	their	membranes	by	
sonopora7on.		
Figueiredo	&	Esenaliev	J	Drug	Deliv	2012	
a	
b	
Real-7me	confocal	imaging	of	membrane	perfora7on	and	recovery	
in	sonopora7on	induced	by	a	single	2um	microbubble	adhered	to	
an	anchored	ﬁbroblast	
Hu	et	al	Ultrasound	in	Med	&	Biol	39:2393	(2013)			
Current	studies	
1) Low frequency ultrasound as 
antibacterial therapy  
 
Alternative to antibiotics in chronic wound infections 
 
Guma Beleid, PhD student 
Dr Prachi Stafford 
Dr Keith Miller 
Infected	TE	skin	model	
Shepherd J et al Tissue Eng Part C 15:475 (2009)   
Human	skin	H&E	
TE	skin	infected	with	S.aureus	(Gram)	
TE	skin	H&E	
TE	skin	infected	with	P.aeruginosa	(Gram)	
At 50kHz, treatment of S.aureus both in suspension and in 
an infected tissue engineered model of human skin are 
sufficient to substantially reduce numbers of viable bacteria 
(Shepherd & Rose, unpublished data).  
S.aureus	infected	skin,	50kHz,	5	mins	
Guma’s PhD Aim:  
To investigate low frequency ultrasound as antibacterial 
treatment on planktonic bacteria and bacteria grown as 
biofilm on TE infected skin model 
 
40kHz	
US	at	40kHz	kills	planktonic	bacteria	
Protein	is	released	into	media	
following	US	indica7ng	cell	
rupture	
NEXT:	US	treatment	of	infected	skin	
2)	Eﬀects	of	a	novel	ultrasound	device	on	
wound	healing	and	bioﬁlm		
•  Project	funded	by	Smith	&	Nephew		
•  Dr	Toby	Holmes	
•  Using	the	infected	TE	skin	model	
– Our	bioﬁlm	is	robust	
– Long	term	eﬀects	of	US	coupling	gel	on	skin		
3) ‘Waking up’ bacteria 
 
•  Low frequency/low intensity US as a method of 
making biofilm bacteria more susceptible to 
antibiotics  
•  Evidence suggests low  
frequency, low intensity  
US might increase bacterial 
metabolism 
•  Can we ‘wake up’ dormant bacteria (‘persisters’) in 
biofilm so they will be more susceptible to 
antibiotics? 
PiT	&	Ross,	2003	
																																S.epidermidis	
+	Ultrasound																																						-Ultrasound		
‘LIPUS’	Exogen	US	bone	healing	system	
20	minute	treatment	of	P.aeruginosa	in	
sta7onary	phase	with	Exogen	(pulsed,	
1MHz)	increases	OD600	ager	24h	by	
~25%	
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OD	(600nm)	 Crystal	violet	
•  Persisters	more	
resistant	to	
gentamicin	
•  Treatment	with	US	
makes	persisters	
more	suscep7ble	
to	gentamicin	
Exogen	makes	persisters	more	sensi0ve	
to	an0bio0cs	
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…also	eﬀec7ve	with	S.aureus	
S.aureus	S235	persister	cells	
4)	‘Bug	Disco’	
Dr	Mark	Murphy,	
Liverpool	John	Moores	
University	
Acous7c	vibra7on	(not	ultrasound!)	enhances	the	
forma7on	of	P.aeruginosa	and	S.aureus	bioﬁlm	
Dr	Fred	Bezombes,	
Liverpool	John	Moores	
University	
0Hz	(P.aeruginosa)	 100Hz	(P.aeruginosa)	 100Hz	(S.aureus)	
Murphy,	Edwards,	Hobbs,	Bezombes	&	Shepherd	-	(J.	Bioscience	&	Bioengineering	2016,	
manuscript	submiTed)	
Crystal	violet	assay	-	P.aeruginosa	or	S.aureus	subjected	
to	acous0c	vibra0on	for	48h		
P.aeruginosa	 S.aureus	
0	
0.5	
1	
1.5	
2	
2.5	
0Hz	 100Hz	 400Hz	 800Hz	 1600Hz	
O
p0
ca
l	d
en
si
ty
	a
t	5
70
nm
	
0.00E+00%
5.00E+09%
1.00E+10%
1.50E+10%
2.00E+10%
2.50E+10%
3.00E+10%
3.50E+10%
4.00E+10%
4.50E+10%
5.00E+10%
Planktonic% Bioﬁlm%
N
o.
$o
f$b
ac
te
ria
/m
l$
0Hz%
400Hz%
800Hz%
P.aeruginosa	
US	in	Opthalmology	
•  US	mainly	used	for	imaging	ocular	pathology	&	anatomy	–	a	
superﬁcial	ﬂuid	ﬁlled	structure	
•  Two	main	types	of	ultrasound	used	in	ophthalmologic	
prac7ce:	
–  A-scan:	8	MHz	-		obtaining	globe	length	to	calculate	correc7ve	
lens	power	requirements.	
–  B-Scan:	10	MHz			-	Frequently	used	to	examine	re7na	in	diabe7c	
pa7ents	who	have	developed	vitreous	hemorrhage	to	
determine	whether	they	have	developed	a	re7nal	detachment.	
Also	used	for	measurement	of	tumors							
•  Improved	visualiza7on	of	structures	obscured	by	opaque	
substances,	such	as	dense	cataracts	or	vitreous	
hemorrhage.		
A	scan	-		rou7ne	
diagnos7c	test.	Provides	
data	on	the	length	of	the	
eye,	a	major	
determinant	in	common	
sight	disorders.		
B	scan	–	imaging	
similar	to	CT-scan.	
Can	US	be	used	to	enhance	delivery	of	
an0bio0cs	into	the	eye?		
•  Nabili	et	al	(2013)	–	5	min	
treatments	of	US	plus	
dexamethasone	to	rabbit	corneas	
to	see	if	US	could	overcome	
barrier	proper7es	of	cornea	
•  Permeability	of	cornea	to	
dexamethasone	but	not	
tobramycin		increased	at	400	KHz	
•  Histological	analysis	showed	
structural	changes	limited	to	
epithelial	layers	of	cornea	
Sham	
400	KHz	&	1	w/cm2	
1	MHz	&	1	W/cm/2	
600	KHz	&	1	w/cm2	
Poten0al	of	using	an0microbial	
polymers	in	US	gel?	
•  US	gel	is	bacteriosta7c	
•  Cross-infec7on	is	a	problem	
•  Norris	et	al	(2005)	–	designed	a	drug	delivery	
polymer	matrix	of	pHMEA	hydrogel	coated	with	
ordered	methylene	chains	which	form	a	US-
responsive	coa7ng	
–  Ciproﬂoxacin	retained	within	polymer,	released	on	43	
kHz	US	irradia7on	
		
Methylene 
chain-coated 
pHEMA 
hydrogel & 
P.aeruginosa 
No US 
No ciprofloxacin 
US 
No ciprofloxacin  
No US 
Ciprofloxacin   
US 
Ciprofloxacin 
Norris et al 
(2005) 
Antimicrobial 
agents and 
chemotherapy 
49:4272 
•  Accous7c	waves	aﬀect	both	the	amount	of	bioﬁlm	and	
bioﬁlm	paTerning	according	to	frequency	and	
amplitude…	
•  Low	frequency	high	intensity	ultrasound	reduces	viable	
bacteria	numbers	in	suspension,	on	an	infected	TE	skin	
model	and	also	intracellularly	within	infected	ECs….	
•  Low	frequency	low	intensity	pulsed	ultrasound	may	
encourage	growth	of	bioﬁlms	by	increasing	bacterial	
metabolism	-	making	them	more	suscep7ble	to	
an7bio7cs	….	
Research	in	progress	
Thank	you!	
UoS	
•  Ian	Douglas	
•  Sheila	MacNeil	
•  Craig	Murdoch	
•  Graham	Staﬀord	
•  Ilida	Ortega	Asencio	
•  Tom	Paterson	
•  Toby	Holmes	
SHU	
•  Guma	Beleid	
•  Prachi	Staﬀord	
•  Keith	Miller	
Smith	&	Nephew	
•  Iain	Webster	
•  Tony	Dagger	
•  Dan	Fitzgerald	
	
LJMU	
•  Mark	Murphy	
•  Frederic	Bezombes	
•  Tom	Edwards	
Quorum sensing and antibiotics tolerence    
Subhadeep Chatterjee
St ff S i ti ta  c en s
Laboratory of Plant Microbe Interaction
Centre for DNA fingerprinting and Diagnostics
(CDFD), Hyderabad 
¾Q iuorum sens ng.
¾How quorum sensing contribute to antibiotics
tolerance.
¾Heterogeneity in quorum sensing.
¾Targeting social behavior of microbes: 
social drugs.
Community
Solitary
Solitaryociomicrobiology
In prokaryotes, quorum sensing is called as 
density dependent cell-cell signaling
Small chemical molecules
High cell densityLow cell density
Bacteria can count and recognize each other by their 
language
Bacteria love to talk like human
Bacteria making 
chemical signal
d lki i h
Bacteria which is 
not able to 
an  ta ng w t
each other
speak
Bacterial language molecules
DSF
Sometimes, bacteria can speak in two or more 
different languages
Telugu
Hindi
English
Bengali
Host signals 
and defense
molecules EffectorsToxinExtracellular
TIIISSTISS
TIISS
 
enzymes
DSF
Quorum sensing 
?
Vi l l ti
FF h /
ru ence gene regu a on
Flagella
Pili rp avrTwo component signal transduction
PSA
PSA+1mM Acetosyringeone
Xom
rpfF
CG8
PSA+0.1 % Tween 20 PSA+0.2 %Triton x 100
PSA+ 0.01 % SDS PSA+10mM NaCl
Xoo 24 h 
2 5D View.  
Biofilm formation in  
air- media interphase

DSF promotes attachment and 
biofilm formation
W T rpfF rpfF/CG8
B
2
2.5
**
***
1
1.5 *
0
0.5
WT rpfF rpfF/CG8 rpfF + 30 
µM DSF
C WT rpfF rpfF/CG8
XadADSF positively regulates 
adhesins: XadA, YapH, FimA
Integration of iron and quorum sensing
NON-VASCULAR PATHOGEN
Symptoms of 
Bacterial Leaf Streak
in Xanthomonas oryzae caused by X. oryzae
pv. oryzicola
Ferric citrate
TonB 
protein
TonB 
recept
or
EPS LPS
Quorum sensing
T2S
system
Siderophore
Ferric 
ABC permeases
- Fe2+
-SiderophoreRpfF
Fur
Zur     FhrR
F 2+
DSF
T3S
Adhesins
e
system
Rai et al., Molecular Microbiology, 2015.
Quorum sensing: Density dependent fitness benefit
‘Public goods’
‘Private goods’ 
Social behavior:
Exo enzymes
Biofilm
Altruism Conflict
Adhesin
Antibiotic tolerance
motility
QS synchronizes cells in the population to perform       
collective social tasks in unison which maximize 
the benefit at the inclusive fitness of individuals 
Phenotypic heterogeneity in performing 
social tasks is advantageous as it can 
serve as a bet-hedging survival strategy 
under changing environmental 
conditions.
Do bacteria exhibit bet hedging in QS?   -    
Extracellular signal   
concentration
Intracellular signal 
concentration
2.5300
a
t
 
Dynamics of QS response 
of single cells in the population:
1
1.5
2
150
200
250
n
t
r
a
t
i
o
n
 
(
O
.
D
 
a
0
n
m
/
m
l
)
e
s
c
e
n
c
e
AHL Unit
     
How individual cells behave 
0
0.5
0
50
100
0 20 40 60 80
C
e
l
l
 
c
o
n
c
e
6
0
0
F
l
u
o
r
e
O.D at 600 
nm/ML
in QS activated population?
Time (H)
Pseudomonas syringae 
pv. syringae (Pss) Xanthomonas campestris pv. campestris (Xcc)A B
E. coli (JB524)
C
ahlI ahlR rpfF rpfC
pahlI
luxR gfp
PluxI
AhlI
AhlR
(+)
RpfF RpfC LuxR (+)
AHL
RpfG
(+)
DSF
AHL
PahlI
gfp
+
peng
gfp
Peng
eng
A B
16
18
90
100
14
16
90
100
Pss B728a-PahlI::gfp Xcc 8004-Peng::gfp 
s
c
e
n
c
e
/
m
l
)
]
10
12
14
60
70
80
F
U
/
m
l
)
]
10
12
60
70
80
r
e
s
c
e
n
c
e
%
 
c
e
l
l
s
m
a
l
i
z
e
d
 
G
F
P
 
f
l
u
o
r
e
s
d
e
n
s
i
t
y
 
[
L
o
g
 
(
C
F
U
/
6
8
30
40
50
%
 
c
e
l
l
s
u
r
e
 
d
e
n
s
i
t
y
 
[
L
o
g
 
(
C
F
4
6
8
30
40
50
o
r
m
a
l
i
z
e
d
 
G
F
P
 
f
l
u
o
C
e
l
l
‐
n
o
r
m
C
u
l
t
u
r
e
 
0
2
4
0
10
20
0 8 16 24 32 40 48
C
u
l
t
u
0
2
0
10
20
0 8 16 24 32 40 48
C
e
l
l
‐
n
o
Time (h)
Time (h)
Low QS signal                       High QS signal
Biofilm
(sessile)
Planktonic
(Motile)
Biofilm matrix
QS uninduced
QS induced
QS i l s gna
Molecular Microbiology; (2014)92:557-569


Strategies to interfere cell cell signaling in plant pathogen        
Degradation of signaling molecule
Overproduction of signaling molecule
 Altering the signaling molecule for causing pathogen confusion       
M t f Di b ll ll i lianagemen  o  sease y ce  ce  s gna ng 
interference
Transgenic
Non transgenic-
S i l d ti i bi l toc a  rugs as an -m cro a  agen
Quorum Sensing system in bacteria

An update on the response of functional polymers to cell based 
targets
Stephen Rimmer 
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Based	on	textiles	
Now	regenerating
Smart polymers and stimuli
∆T
∆pH 
Can  we mimic biological “smartness” 
       
   binding         conformational (folding) change
Some	features	of	branched	polymers	
Chain	ends	
	 -functional	
	 -many
Branch	points	
	 	 -different	structures	to	repeatsNo	reptation	
No	or	very	little	inter-segment	penetration	
Low	viscosity	
Useful	for	carrying	functionality-as	additives	
Some consequences of branching: chain ends do not penetrate the coil 
Chain ends  
expressed in outer domains 
available for binding to cells 
shielded in inner domains 
not available for binding 
>LCST 
<LCST
>LCST 
<LCST
Self-condensing RAFT copolymerisation
Carter et al Macromolecules  38, 4595, (2005) 
Carter et al Macromolecules  38, 4595, (2005) 
Bacteria-binding ligands
• Branched poly(NIPAM) - antibiotics  @ chain ends 
  
Vancomycin – binds Gram+ve (S.aureus) 
Polymyxin-binds Gram-ve (P. aeroginosa) 
J. Shepherd et al J. Am. Chem. Soc., 132 1736 (2010)
React with COOH on  polymer
 P. Sarker et al Biomacromolecules, 12 1 (2011)
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GPC with viscometric detection
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Using the Mark Houwink relationship α   tells us about coil shape 
α			<	0.5	indicates	a	compact	(branched)	structure	
Branching and End groups
Rimmer et al Soft Matter 3 971 (2007)
Arg-Gly-Ser 
COOH
With polymer forms a mat
S. aureus                 HB-PNIPAM +S. aureus           HB-PNIPAM+P. aeruginosa  
S. aureus
S. aureus responsive polymers
No polymer forms a button
[Polymer] /mg ml-1
HB-PNIPAM-pmx with P. Aeroginosa: Gram-ve
14
Sarker et al Soft Matter 10 5824 (2014)
Forster Energy Transfer used to prove binding induced transition 
15
Synthesis of double labelled polymers 
16
Fluorescence decay curves 
Water                                       S. aureus
HB-P[(NIPAM-co-AMMA[1%])-block-(NIPAM)]-Van
HB-P[(NIPAM-co-AMMA[1%])-block-(NIPAM-co-FA[2%])
Conclusion 
Branched PNIPAM with vancomycin end groups does indeed pass 
Through the coil-to-globule transition on binding to S.aureus
17
       Linear compared to branched
vancomycin
L-PNIPAM-Van
HB-PNIPAM-Van
Transition temp 
DSC         Cloud Pt. 
35 oC  35  oC 
22 oC   not  
      observed
Cloud points and calorimetric LCSTs 
for linear and branched polymers
-COOH-functional polymers in DI water
18
 Control L-PNIPAM-van in PBS 
 L-PNIPAM--van incubated  
with S.aureus in PBS S.aureus in PBS
HB-PNIPAM-van in PBS
HB-PNIPAM-van incubated  
with S.aureus in PBS 
After 24 hours
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USE OF NILE RED -AS A PROBE
◆ Solvatochromic dye 
◆ Spectrum changes as polarity changes 
◆ Also fluorescence intensity increases 
  as polarity decreases 
 
◆ Added to polymer solutions  
◆      plus bacteria 
◆ Only a small shift in λmax  
◆ but fluorescence intensity increases 
Behaviour of Nile Red probe as branching increases
Further look at Nile Red in a range of polymers with COOH end groups and changing degrees of 
branching 
LCSTs decrease as degree of branching increases.  
However, using the Nile Red λmax:
W
av
el
en
gt
h 
/ n
m
620
630
640
650
660
Temperature oC
5 14 23 32 41 50
Decreasing LCST
No change at high  
degrees of branching 
But a LCST does occur
21
An improved model
◆ λmax does not change much for Nile red in polymers of high degrees of branching 
◆ Fluorescence intensity is enhanced 
◆ With Vancomycin we do not see a cloud point but we do see a LCST in µDSC 
◆ FRET shows that coil-to-globule transition does occur on binding 
So Nile red can be partitioned in globular AND open chain domains 
-fluorescence intensity changes seen because this is more sensitive 
In Vancomycin polymers the end groups are charged 
And provide electrostatic colloidal stability 
  - no aggregation= no cloud point
Polar end groups “penetrate the shell”
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Discusssion sessions 
 
Antimicrobial resistance is an important area for international collaboration. As well 
as reporting our work and introducing this multi-discipinary group to various aspects 
from different fields we engaged in several discussions. 
 
The outputs from these discussions were two areas that the group felt deserved much 
greater attention and could form large programmes with great impact in the field. The 
following summarises these two identified themes, which we intend to work on 
further over the next 12 months.    
 
 
Theme 1. Sustained and targeted drug delivery 
 
Stephen Rimmer and Vamsi Krishna Venuganti 
 
1.Background 
 
1.1 Delivery of antimicrobial agents will be critical to combating resistance and to 
optimum use of both current and new drugs. By considering and optimising drug 
delivery strategies we can: 
 
• Deliver at high concentrations above the minimum resistance concentration 
(MRC) 
• Target and use topical applications 
• Reduce the exposure of non-infected organs to antibiotics 
• Minimise toxic and tissue damage effects and facilitate the use of a wider 
range of compounds 
• Consider the effective use of macromolecular drugs-e.g. antimicrobial 
peptides 
 
1.2 Current delivery strategies in this area appear to be under developed and 
systemic delivery of antibiotics is the norm. This brings issues such as the well-
known onset of Candida infections and the deleterious effects on gut micro biota. 
 
Many current strategies are aimed at slow release but this is not appropriate for 
antimicrobial delivery, which requires sustained high local concentrations of antibiotic.
 
Many systems for targeted delivery have not worked in vivo: problems with non-
specific interactions; masking of ligands and poor stability of complex structures (e.g. 
unsuitable in vivo stability of vesicles etc.).  
 
High drug loadings are key to this area and this will require new systems because 
many of the current (e.g. amphiphilic block copolymer vesicles) cannot support the 
required concentrations. This will almost certainly limit the useful systems to solid or 
lamellar morphologies; either in particle, fibre or membrane form.  
 
2 Aims of delivery systems 
 
2.1 The delivery requirements for antimicrobials are quite different to other drugs. 
Key features are: 
• Targeting to bacteria avoiding tissue. This will allow for the use of drugs that 
might otherwise damage tissue if delivered systemically. 
• Rapid release locally 
• High concentration sustained delivery 
• Local delivery in preference to systemic delivery  
• Delivery over 24 hours without redosing 
 
2.2 Some requirements for multi-drug delivery. High local delivery may in some 
cases be required with multiple drugs; e.g. antibacterial and anti-fungal 
 
3. Opportunities from workshop 1, Hyderabad, 14th-15th March 2016 
 
3.1 Ionphoresis can be used to progress charged particles through tissue. This is a 
very useful technology and requires only charged particles to be effective.  Charge 
degradable polymer particles can easily be made with dimensions from 50 -1000 nm 
using techniques routinely used by a number of the chemistry teams within the 
group. Possible charged systems, which can be optimsed for ionphoresis, include: 
• Graft copolymer and block copolymer micelles with and without end group 
targeting ligands Graft copolymer and block copolymer lamellar, layer by layer 
and onion structures, with and without end group targeting ligands 
• Highly branched, hyper branched and dendrimer systems 
• Core shell emulsion particles 
• Imprinted polymer colloids 
 
 
3.2 Multiple drug delivery can be achieved by: 
• Simple mixing of drugs; however there may be issues with compatibility and 
mixing 
• Using multi-domain particles; e.g. core shell particles 
 
3.3 Antimicrobial peptides have been available for some time but issues with non-
adoption include cost and lack of systems for delivery. There are issues with toxicity 
and it is not possible to administer systemically. New solutions include: 
• Delivery by complexing with oppositely charged polymers that mask some of 
the tissue toxicity 
• Enhanced targeting with charged particulate hydrogels 
• Using shorter key sequences 
 
3.4 Targeting has been an area that received a significant amount of attention but 
progress into the clinic has been difficult. A significant aspect is that polymer bound 
ligand affinity is much reduced in vivo. Recent results show that by placing the 
ligands at chain ends, in either branched polymers, block copolymers or low molar 
mass oligomers, targeting efficiencies are vastly increased. The design of the most 
successful “linear polymers” for targeting cancer already have ligands at the end of 
“spacers” but these were designed without the key concepts that we have now 
developed here. In effect these spacer systems are graft copolymers with the ligands 
at the chain ends and the principles of their action are the same as the principles at 
work in the successful targeting using highly branched polymers; i.e. location of 
chain ends at the outer domains of the polymer coil or globule in branched polymers 
preventing shielding.  Using this concept, drug delivery systems can be targeted to 
infective sites using: 
• Highly branched polymers with ligands at chain ends 
• Graft copolymer micelles with ligands at chain ends of the hydrophilic 
branches (this is similar to the essential use of spacer arms in the current 
linear polymer targeting systems) 
• Block copolymer micelles with ligands at the chain ends of the hydrophilic 
branches 
  
 
Theme 2. Designing new diagnostic test that can help physicians start 
appropriate/targeted treatment 
 
Prashant Grag and Ian Douglas 
 
Classically the identification of microorganisms involves the collection of test 
samples and subjecting these to detailed microbiology work-up consisting of 
microscopic examination and inoculation of specimen on various culture media 
followed by a battery of biochemical tests for the identification of the growth on these 
media. This approach has several disadvantages: 
1. This approach requires a well-equipped and standardized microbiology 
laboratory. Since most laboratories are located in urban areas physicians in 
semi-urban and rural areas specially in developing nations do not have 
access to such laboratories.  
2. Ordering such tests involves additional cost. The health system or patients 
often find it difficult to bear this cost.  
3. The identification of microorganisms and antibiotic susceptibility tests take 3-5 
days. Untill this time patients are treated empirically.  
4. Like any other test microbiology tests have false positive and negative results 
and the test results need to be interpreted keeping this in consideration. 
Therefore, a negative microbiology does not rule out infection and a positive 
test does not always means disease being caused by the identified pathogen. 
 
All of the above factors force physicians to use antibiotics and other antimicrobial 
agents empirically thereby adding to the problem of drug resistance.  
Therefore, one of the approaches to prevent indiscriminate use of antibiotics will be 
to develop simple to use bedside tests that have high sensitivity and specificity and 
provide results in the shortest possible time (few hours) and without the need to 
engage sophisticated laboratory facilities.  
 
The workshop participants considered this as one of the crucial aspects and 
discussed different approaches for which the group had good knowledge of science 
and expertise to plan and execute collaborative research projects.  The following 
possibilities were discussed: 
• Tests based on the use of bacteria binding functionalized polymers: a 
significant body of work is already in progress and was presented in part by 
Prof Rimmer during the workshop. The work is being carried out through a 
joint Wellcome Trust grant awarded to the University of Sheffield and the 
University of Bradford in UK and L V Prasad Eye Institute, Hyderabad in India. 
These responsive polymers are described in a series of publications, in which 
the group showed that by placing bacteria binding ligands at the chain ends of 
highly branched poly (N-isopropyl acrylamide) (HB-PNIPAM) it is possible to 
induce a phase transition in the polymer on binding. The phase transition 
involves switching the polymer from an open and fully solvated state into a 
desolvated and more compact state. Also, the globular state produces a less 
hydrophilic environment than the coil state. This change can be detected by 
techniques incorporating environment sensitive dyes (solvatochromic dyes). 
• Bio-sensers based on specific signals produced by microorganisms: 
Biosensors are defined as analytical devices incorporating a biological 
material or a biologically derived material or a biomimetic intimately 
associated with or integrated within a physicochemical transducer or 
transducing microsystem, which may be optical, electrochemical, 
thermometric, piezoelectric, magnetic or micromechanical. 
 The technique involves immobilization of biological recognition elements 
 using either of enzymes, antibodies or DNA probes followed by their 
measurements using optical, electrochemical, thermometric or magnetic 
techniques. There was a lot of interest in exploring different biological 
recognition elements for the identification of pathogenic bacteria and the 
group considered to include this as one of the key elements for developing 
future collaborative research.  
• Tests based on Metabolomics: Dr Ghosh discussed use of metabolomics for 
the identification of microorganisms. The study of metabolome – the complete 
set of metabolites produced within an organism – is a reflection of enzymatic 
pathways and networks encoded within the genome. Additionally, the entire 
composition of metabolites conveys the interplay of developmental processes 
and a changing environment over the lifetime of an organism. By studying 
metabolomics we can not only identify the presence of pathogenic 
microorganisms but also get information on the global outcome of various 
factors acting on the cell, as well as an accurate snap shot of the actual 
physiological state of the organism. The group also considered the cost of the 
apporach and feasibility of use by general physicians practicing in rural or 
semi-urban areas.  
The discussion concluded with majority vote to explore couple of these approaches. 
The participants will try to develop collaborative grant proposal incorporating these 
various approaches.   
 
 
